Methods of treating hidradenitis suppurativa using lou064

TWI945399BActive Publication Date: 2026-11-11NOVARTIS AG
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
TW112107010
Authority / Receiving Office
TW · TW
Patent Type
Patents
Current Assignee / Owner
Priority Date
2022-07-21
Filing Date
2023-02-24
Publication Date
2026-11-11
Estimated Expiration
2043-02-23

AI Technical Summary

Technical Problem

Current treatments for hidradenitis suppurativa (HS) are inconsistent, lack evidence-based data, and often have adverse effects, with a need for safe and effective long-term therapies, particularly oral treatments.

Method used

Administering a therapeutically effective dose of a selective Bruton's tyrosine kinase (BTK) inhibitor, such as LOU064, which is selective for BTK but not Tec kinases, to treat or prevent HS.

Benefits of technology

LOU064 effectively reduces inflammatory lesions, pain, and itch in HS patients, with sustained responses up to three months after treatment, and demonstrates a favorable safety profile over extended use, avoiding common side effects of other BTK inhibitors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure TWG2TB001920144_001
    Figure TWG2TB001920144_001
  • Figure TWG2TB001920144_002
    Figure TWG2TB001920144_002
  • Figure TWG2TB001920144_003
    Figure TWG2TB001920144_003
Patent Text Reader

Abstract

This disclosure relates to methods for treating and / or preventing hidradenitis suppurativa in subjects, methods comprising administering a therapeutically effective dose of LOU064. It also discloses the drugs, dosing regimens, drug components, combinations, dosage forms, and kits used in the disclosed uses and methods.
Need to check novelty before this filing date? Find Prior Art

Description

Methods of treating hidradenitis suppurativa using LOU064 This invention relates to LOU064 or a pharmaceutically acceptable salt thereof for use in the effective and safe treatment of hidradenitis suppurativa (HS). Hidradenitis suppurativa (HS) (also known as acne inversa or Verneuil's disease) is a chronic, relapsing, inflammatory disease characterized by deep nodules, sinus tracts, and abscesses leading to fibrosis in the axilla, groin, breast folds, and anogenital region. (Revuz and Jemec (2016)) Dermatol Clin 34:1-5; Jemec GB. (2012) N Engl J Med [New England Journal of Medicine] 366:158-64). It is associated with severe pain and comorbidities, including metabolic disorders, mental disorders, and autoimmune disorders, as well as an increased risk of skin cancer. (Revuz (2016); Shlyankevich et al. (2014)) J Am Acad Dermatol [Journal of the American Academy of Dermatology] 71:1144-50; Kohorst et al. (2015) J Am Acad Dermatol [Journal of the American Academy of Dermatology] 73:S27-35; Wolkenstein et al. (2007) J Am Acad Dermatol [Journal of American Academy of Dermatology] 56:621-3). The average prevalence of HS by race / ethnicity was highest in African Americans (1.3%), lowest in Hispanics / Latinos (0.07%), and in the middle in Caucasians (0.75%) (Sachdeva et al. (2021) J. Cutan Med Surg. [Journal of Dermatology and Surgery]: 25(2):177-187. The reported prevalence of HS varied from <1% to 4% in the population. [Shlyankevich et al. (2014); Cosmatos et al. (2013)] J Am Acad Dermatol [Journal of the American Academy of Dermatology] 68:412-9; Davis et al. (2015) Skin Appendage Disord 1:65-73; Revuz et al. (2008) J Am Acad Dermatol [Journal of the American Academy of Dermatology] 59:596-601; McMillan K. (2014) Am J Epidemiol 179:1477-83; Garg et al. (2017) J Am Acad Dermatol, 77(1):118-122; Jemec et al. (1996) J Am Acad Dermatol [Journal of the American Academy of Dermatology] 35:191-4]. However, due to underdiagnosis of HS, it is difficult to determine the true prevalence, and the estimates fluctuate with study design, population, and geographic location. [Miller et al. (2016)] Dermatol Clin 34:7-16]. Although the National Institutes of Health (NIH) does not classify HS as a rare disease, experts generally believe that its prevalence is <1% in the US population. [Cosmatos et al. (2013); Genetic and Rare Diseases Information Center. National Institutes of Health. Hidradenitis suppurativa. See: / / rarediseases.info.nih.gov / diseases / 6658 / hidradenitis-suppurativa. Accessed March 20, 2017; Gulliver et al. (2016)]. Rev Endocrine and Metabolic Disorders Review 17:343-51; Garg et al. 2007). Current treatments for HS include local and / or systemic antibiotics, hormonal interventions, and, where appropriate, immunosuppressants and biologics (such as the tumor necrosis factor [TNF] inhibitor monoclonal antibody adalimumab, which is the only approved drug for HS and is usually used as a last resort after major surgical resection). [Gulliver et al. (2016); Zouboulis et al. (2015) J Eur Acad Dermatol Venereol [European Association of Dermatology and Venereology Journal] 29:619-4414-16; Kimball et al. (2016) [N Engl J Med [New England Journal of Medicine] 375:422-34]. Because the lesion is painful, patients often require analgesics and pain relief in addition to anti-inflammatory treatment. However, symptom control and lesion regression are inconsistent between treatments, and most treatments lack evidence-based randomized controlled clinical trial results, with only adalimumab being approved. Although antibiotic therapy is used for long-term treatment lasting months or even years, it can lead to relapses of antibacterial resistance. Oral treatment with retinoids raises concerns about teratogenicity in sexually active, predominantly female populations. Furthermore, the effectiveness of inflammatory drugs (such as diamine benzoate, fumarate, and cyclosporine) is based on small case studies with varying results, and these molecules are not used systematically. Due to these inconsistent results and the severity of HS, patients with HS use healthcare more frequently in high-cost settings (e.g., emergency departments and inpatient care) compared to patients with other chronic inflammatory skin conditions. (Khalsa et al. (2016)) J Am Acad Dermatol [Journal of the American Academy of Dermatology] 73:609-14; Kirby et al. (2014) JAMA Dermatol [Journal of the American Medical Association Dermatology] 150:937-44). The immunopathogenesis of hepatitis B (HS) is poorly understood, with a wide range of proposed mechanisms. Complement activation is associated with the pathogenesis of HS by increasing the concentration of complement fragment C5a in the skin and blood of patients with the disease (Kanni T. et al.). Br J Dermatol. [British Journal of Dermatology] 2018;179(2):413–419). C5a is the main chemotherapeutic agent of neutrophils, which is a prominent cell population in the skin of active inflammatory HS (Lima AL. et al.). Br J Dermatol. [British Journal of Dermatology] 2016;174(3):514-520). Furthermore, increased levels of neutrophils releasing extracellular traps of neutrophils (NETs) have been demonstrated in both the blood and skin of patients with HS during a process known as NETosis (Byrd AS et al.). Sci transl Med. [Science Translational Medicine] 2019: 11(508).eaav5908), and increased type I IFN response and activation of plasmacytoid dendritic cells (pDCs). Other studies have shown that pro-inflammatory interstitial cytokines IL-17A and IFN-γ (Hotz C. et al.; J. Invest Dermatol. [Journal of Dermatological Research], 2016:136(9):1768-1780; Vossen ARJV et al. Allergy. 2019, 74(3):631-634), and keratinocyte-derived IL-6 and IL-1β are involved. Other transcriptomic studies have noted increased expression of immunoglobulins and plasma cell signatures in HS (Hoffman LK et al.). PLoS One. [PLoS One] 2018; 13(9):e0203672), but lacks a clear and comprehensive understanding of the immunopathogenic mechanisms involved in HS. Gudjonsson et al. used proteomics and transcriptomics methods, as well as methods such as single-cell RNA sequencing or scRNAseq, to ​​characterize the inflammatory response in HS in depth. Such studies revealed an immune response centered on IFN-γ, IL-36, and TNF, with a smaller contribution from IL-17A. Gudjonsson et al. further identified B cells and plasma cells, accompanied by increased immunoglobulin production and complement activation, as participants in the pathogenesis of HS, in which Bruton's tyrosine kinase (BTK) and spleen tyrosine kinase (SYK) pathways activate the central signal transduction network of HS (JCI Insight. [Journal of Clinical Research Sub-Journal Mechanism Analysis] 2020;5(19):e139930. https: / / doi.org / 10.1172 / jci.insight.139930). The role of B cells in the pathogenesis of hepatitis B (HS) has been previously reported (Van der Zee et al. 2012, 166:98-106; Musilova et al.). J Invest Dermatol [Journal of Dermatological Research] 2020, 140:1091-1094. Furthermore, two recent studies have highlighted the role of B cells in the pathogenesis of HS: one study demonstrated the anti-inflammatory effect of rituximab in HS explant cultures (Vossen et al., 2019, 181:314-23), and another case study showed successful treatment of HS using rituximab to deplete B cells (Takahashi et al., 2018, 45:e116-7). However, further research is needed to determine whether targeting B cells is an effective treatment. BTK is a kinase essential for communication via FcεRI in human mast cells and basophils. Because it is also crucial for B cell maturation, BTK has been pharmacologically targeted for the treatment of B-cell malignancies. Currently, there are three FDA-approved BTK inhibitors (BTKi) in the United States: ibrutinib (brand name Imbruvica®; Pharmacyclics, Inc. and AbbVie), acalabrutinib (Calquence®; Acerta, Inc. and AstraZeneca), and zanubrutinib (Brukinsa®; BeiGene, Inc.) are all oral, covalent small molecule inhibitors of BTK. In addition, many BTKi under development are in clinical trials for the treatment of autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus. For example, acalabrutinib and zanubrutinib, as well as novel compounds ONO-4059 (tirutinib), HM71224 (persertinib), and ABBV-105 (utpatinib), are currently being tested for their efficacy against B-cell malignancies and / or autoimmune diseases such as rheumatoid arthritis (RA), Sjögren's syndrome (SjS), and systemic lupus erythematosus (SLE). Furthermore, evapotinib, tolebrutinib, and fenetinib have entered Phase III studies in patients with multiple sclerosis (MS), orelabrutinib is being tested in a Phase II study, and BIIB091 is being tested in a Phase I study for its efficacy in treating MS. Although some believe BTK inhibitors could be used to treat hepatitis B (HS), there are currently no animal models of this disease, and BTK inhibitors have not been shown to treat HS in humans. Furthermore, due to the lack of selectivity of some early-developed BTK inhibitors (such as acalatinib and ibrutinib), these BTK inhibitors may not be suitable for non-malignant indications, especially for treatments requiring long-term / prolonged and safe use and / or indications in children or adolescents. The most common side effects of currently approved BTK inhibitors include nausea, diarrhea, rash, infection, cytopenia, bleeding, and arrhythmias. In particular, the long-term toxicity profile of ibrutinib (a first-in-class inhibitor) is well characterized and includes a clinically significant incidence of arrhythmias, bleeding, infection, diarrhea, arthralgia, and hypertension. Acalatinib (the first second-generation BTKi approved by the U.S. Food and Drug Administration) demonstrated improved kinase selectivity for BTK, with commonly observed adverse reactions including infection, headache, and diarrhea (Hematology Am Soc Hematol Educ Program. 2020 Dec 4; 2020(1): 336–345). Currently, there is a lack of long-term safety data for BTK inhibitors under development. However, the available safety data for fenestrinib suggests that the biggest hurdle for BTK inhibitors may be whether side effects are acceptable during prolonged use. For example, a major event noted in the phase IIa trial of fenestrinib was transient grade 3 elevations in ALT and / or AST in 8.3% and 6.3% of subjects, respectively, in the higher-dose treatment group. Some of the side effects observed with certain BTK inhibitors may limit their use for the treatment or prevention of non-malignant indications, especially in cases requiring long-term administration. Furthermore, none of the FDA-approved BTK inhibitors are approved for use in children and adolescents. Therefore, it remains unclear whether BTK inhibitors will be a viable option until pediatric safety data are available. HS remains difficult to treat, with only one biological therapy currently available (adalimumab, an anti-TNF agent currently approved for its treatment), and even with adalimumab, nearly 40% of patients have a suboptimal treatment response. The disease is both physically and psychologically debilitating, thus there is clearly an unmet need to provide safe and effective long-term treatment (especially oral therapy) for HS patients. The fundamental problem of this invention is to provide a safe and effective treatment or prevention of HS. In particular, the object of this invention is to provide a safe and effective long-term treatment or prevention of HS. Another object of the present invention is to provide improved treatment and / or prevention of HS. For example, one object of the present invention is to provide a more effective treatment or prevention of HS than anti-TNF therapy (e.g., adalimumab). Therefore, this article discloses methods for the prevention or treatment of HS, which include administering a therapeutically effective dose of a BTK inhibitor to a subject in need. Specifically, BTK inhibitors (reversible or irreversible) selective for other structurally similar Tec family kinases (such as BMX, ITK, and TXK) can be used in the methods of this invention. More specifically, BTK inhibitors selective for BTK but not Tec (e.g., at least 10-fold, at least 20-fold, at least 30-fold BTK / tec selectivity) can be used in this invention. This article also discloses methods for the prevention or treatment of HS, which include administering a therapeutically effective dose of LOU064 to subjects in need. Furthermore, the present invention provides a method for treating or preventing HS in a subject in need, the method comprising administering to the subject a therapeutically effective dose of LOU064 or a pharmaceutically acceptable salt thereof, and one or more therapeutic agents. In another aspect of the invention, the invention provides BTK inhibitors for treating and / or preventing HS in patients who require such treatment and / or prevention. In another aspect of the invention, LOU064 is provided for treating and / or preventing HS in patients who require such treatment and / or prevention. The present invention further relates to a combination of LOU064 with one or more other therapeutic agents for the treatment or prevention of HS in patients requiring such treatment and / or prevention. Another subject of the present invention is a method for manufacturing a medicament for use in the aforementioned treatments. Further aspects, advantageous features, and preferred embodiments of the invention, individually or in combination, summarized in the following embodiments E1-E32, contribute to achieving the objectives of the invention: E1. A method for treating or preventing hidradenitis suppurativa (HS), the method comprising administering to a subject in need a therapeutically effective dose of a BTK inhibitor, such as a selective BTK inhibitor, such as LOU064. E2. The method as described in E1, wherein the therapeutically effective dose of LOU064 is approximately 50 mg to approximately 200 mg daily. E3. The method described in E2, wherein the therapeutically effective dose of LOU064 is approximately 25 mg twice daily to approximately 100 mg twice daily. E4. The method described in E2, wherein the therapeutically effective dose of LOU064 is approximately 25 mg twice daily. E5. The method described in E2, wherein the therapeutically effective dose of LOU064 is approximately 100 mg twice daily. E6. The method as described in any of the foregoing embodiments, wherein the LOU064 is administered for a short period, for example less than 6 months, preferably less than 3 months. E7. The method as described in E6, wherein LOU064 is injected over a period of up to 16 weeks, for example, 4, 12 or 16 weeks. E8. The method as described in any one of embodiments E1 to E5, wherein LOU064 is applied for a long period of time, for example, more than 6 months, preferably more than one year, for long-term use. E9. The method as described in any of the foregoing embodiments, wherein LOU064 is administered as a single therapy. E10. The method as described in any of the foregoing embodiments, wherein LOU064 is not administered in conjunction with a strong inhibitor of CYP3A. E11. The method as described in any of the foregoing embodiments, wherein LOU064 is not administered in conjunction with a strong inhibitor of CYP3A4. E12. The method as described in any one of embodiments E1 to E8, wherein LOU064 is administered in combination therapy with one or more therapeutic agents. E13. The method as described in E12, wherein the patient is additionally treated with at least one topical medication and at least one antibacterial agent in combination with LOU064. E14. The method as described in any one of embodiments E1 to E11, wherein the patient has not previously been treated with systemic agents or local treatments prior to treatment with the LOU064. E15. The method as described in any of the above embodiments, wherein the patient is selected according to at least one of the following criteria: a) the patient has moderate to severe HS; b) the patient has at least 3 inflammatory lesions prior to treatment with the LOU064; or c) the patient does not have extensive scarring (no more than 15 fistulas) due to HS prior to treatment with the LOU064; d) the patient has been clinically diagnosed with HS for at least 12 months; e) the patient has at least two anatomical regions associated with HS lesions. E16. The method as described in any of the above embodiments, wherein the patient achieves at least one of the following by week 16 of treatment: a) Simplified HiSCR; b) HiSCR clinical outcome (HiSCR50, HiSCR75, or HiSCR90); c) Reduction of HS redness and swelling; d) Reduction of skin pain as measured by the pain NRS; for example, pain NRS30; e) Reduction of pruritus as measured by the pruritus NRS; for example, pruritus NRS30; f) Reduction of the total count of HS inflammatory lesions or the count of different types of HS inflammatory lesions; for example, AN50, AN75, AN90, or AN100; g) Reduction of IHS4 score; h) Reduction ≤ 6 as measured by DLQI; and / or i) Improvement of DLQI. E17. The method as described in any of the above embodiments, wherein when the method is used to treat a patient population with moderate to severe HS, at least 40% of the patients achieve at least one of the following by week 16 of treatment: a) simplified HiSCR; b) HiSCR50; c) HiSCR75; d) HiSCR90. E18. The method as described in any one of embodiments E1 to E16, wherein when the method is used to treat a patient population with moderate to severe HS, at least 25% of the patients achieve an NRS30 response (e.g., pain NRS30 or pruritus NRS30 response) by week 16 of treatment. E19. The method as described in any one of embodiments E1 to E16, wherein when the method is used to treat a patient population with moderate to severe HS, less than 15% of the patients experience HS redness and swelling during the 16-week treatment period. E20. The method as described in any one of embodiments E1 to E16, wherein as early as one or two weeks after the first dose of LOU064, the patient has at least one of the following: a) pain reduction as measured by the pain NRS (e.g., pain NRS30); b) pruritus reduction as measured by the pruritus NRS (e.g., pruritus NRS30); c) a reduction in CRP as measured using a standard CRP assay, for example, at least 25%. E21. The method as described in any of the above embodiments, wherein the patient achieves a sustained response for 3 months after the end of treatment, as measured by an inflammatory lesion count such as AN50, Hidradenitis Suppurative Clinical Response (HiSCR) (e.g., sHiSCR, HiSCR50, HiSCR75 or HiSCR90), Numerical Rating Scale for Pruritus or Pain (NRS), Hidradenitis Suppurative Physician-Physician Overall Assessment (HS-PGA), Severity Assessment of HS (SASH), International Severity HS Rating System (IHS4) or Dermatology Quality of Life Index (DLQI). E22. The method as described in E21, wherein the patient achieves a sustained response 3 months after the end of treatment, as measured by a simplified HiSCR (sHiSCR), HiSCR50, HiSCR75, or HiSCR90. E23. The method as described in any of the above embodiments, wherein the LOU064 is disposed in a pharmaceutical composition, wherein the pharmaceutical composition comprises one or more pharmaceutically acceptable carriers, each of which is independently selected from fillers, lubricants, binders, disintegrants and flow aids. E24. The method as described in E23, wherein the pharmaceutical composition is in the form of tablets or capsules. E25. The method as described in embodiment E23 or E24, wherein the pharmaceutical composition comprises nanoparticles of LOU064. E26. The method as described in E25, wherein the pharmaceutical composition comprises nanoparticles of LOU064 having an average particle size between about 50 nm and about 750 nm as measured by PCS. E27. The method as described in any one of embodiments E23 to E26, wherein the pharmaceutical composition comprises LOU064 and an adhesive in a weight ratio of about 2:1. E28. The method as described in E27, wherein the pharmaceutical composition comprises LOU064, a binder, and a surfactant in a weight ratio of about 2:1:0.08. E29. The method as described in any one of embodiments E23 to E26, wherein the pharmaceutical composition comprises LOU064 and an adhesive in a weight ratio of about 1:1. E30. The method as described in Embodiment 29, wherein the pharmaceutical composition comprises LOU064, a binder, and a surfactant in a weight ratio of about 1:1:0.05. E31. The method as described in any one of embodiments E23 to E30, wherein the pharmaceutical composition comprises LOU064, a polyvinylpyrrolidone-vinyl acetate copolymer as an adhesive, and sodium dodecyl sulfate as a surfactant. E32. The method as described in any of the foregoing embodiments, wherein LOU064 is an anhydrous free base in crystalline form, characterized by the following X-ray powder diffraction pattern, when measured at a temperature of about 25°C and an X-ray wavelength λ of 1.5405 Å, containing one or more representative peaks, which, in terms of 2θ, are selected from the group consisting of: 7.8 ± 0.2 °2θ, 9.2 ± 0.2 °2θ, 12.0 ± 0.2 °2θ, 13.6 ± 0.2 °2θ, 15.6 ± 0.2 °2θ, 16.0 ± 0.2 °2θ, 17.8 ± 0.2 °2θ, 18.3 ± 0.2 °2θ, 18.7 ± 0.2 °2θ, 19.2 ± 0.2 °2θ, 19.9 ± 0.2 °2θ, 22.1 ± 0.2 °2θ. °2θ, 23.4 ± 0.2 °2θ, 23.9 ± 0.2 °2θ, 24.8 ± 0.2 °2θ, 25.2 ± 0.2 °2θ, 25.5 ± 0.2 °2θ, 27.2± 0.2 °2θ, and 29.6 ± 0.2 °2θ. As used in this article, Bruton's tyrosine kinase (BTK) is a cytoplasmic tyrosine kinase and a member of the TEC kinase family. BTK is expressed in selected cells of the adaptive and innate immune systems, including B cells, macrophages, mast cells / basophils, and platelets. BTK is essential for communication via Fcε receptors (FcεR1 for IgE) and activated Fcγ receptors (FcγR for IgG), as well as B cell antigen receptors (BCRs) and BTK inhibitors. BTK inhibitors such as ibrutinib have been approved for the treatment of B-cell malignancies (Hendriks et al. 2014). Recently, it has been demonstrated that inhibition of BTK leads to inhibition of mast cell and basophil activation / degranulation in vitro and reduces wheal size in skin prick tests in patients with IgE-mediated allergies (Smiljkovic et al. 2017; Regan et al. 2017; Dispenza et al. 2018). Therefore, inhibiting BTK receptors presents an attractive therapeutic concept for treating various autoimmune and chronic inflammatory diseases, including rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, chronic urticaria, atopic dermatitis, asthma, and primary Sjögren's syndrome (Tan et al. 2013; Whang and Chang 2014). Examples of BTK inhibitors include non-covalent, reversible BTK inhibitors such as fenetinib and covalent, irreversible BTK inhibitors such as evapotranib, tolebrutinib, rizarutinib, tirutinib, branebrutinib, orelabrutinib, and ramibrutinib (LOU064). The term "comprising" encompasses both "including" and "consisting of". For example, a composition that "comprising" X may consist of only X or may include other substances, such as X + Y. As used in this article, "pharmaceutically acceptable" refers to compounds, materials, compositions, and / or dosage forms that, to a reasonable medical judgment, are suitable for contact with human and animal tissues without excessive toxicity, irritation, allergic reactions, or other problems or complications (in proportion to a reasonable benefit / risk ratio). The term "about" in relation to a numerical value x means, for example, + / - 10%. When used before a numerical range or a list of numbers, the term "about" applies to each number in the series; for example, the phrase "about 1-5" should be interpreted as "about 1 to about 5", or, for example, the phrase "about 1, 2, 3, 4" should be interpreted as "about 1, about 2, about 3, about 4, etc." As used herein, the term "salt" (or salts) means an acid addition salt or a base addition salt of a compound used in the methods of the present invention. "Salt" specifically includes "pharmaceutically acceptable salts." The term "pharmaceutically acceptable salt" means a salt that retains the bioavailability and properties of the compounds of the present invention and is generally not biologically or otherwise undesirable. In many cases, compounds used in the methods of the present invention are capable of forming acid salts and / or base salts due to the presence of an amino group. Examples of salts are those disclosed in WO 2015 / 079417, which are hereby incorporated by reference. As used herein, the term "administration" for a compound (e.g., LOU064 or another agent) is used to refer to the delivery of the compound to a patient by any route, preferably by oral administration. As used herein, the term "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delay agents, salts, preservatives, drug stabilizers, binders, excipients, disintegrants, lubricants, sweeteners, flavorings, dyes, and combinations thereof, as will be known to those skilled in the art (see, for example, Remington's Pharmaceutical Sciences, 18th edition, Mack Printing Company, 1990, pp. 1289-1329). Except where any conventional carrier is incompatible with the active ingredient, its use in therapeutic or pharmaceutical compositions / formulations should be considered. The term "therapeutic effective amount / dosage" for compounds used in the methods of the present invention refers to the amount of said compound that will elicit a biological or medical response in a subject (e.g., reduce or inhibit enzyme or protein activity, or improve symptoms of HS, alleviate HS symptoms, slow or delay the progression of HS, or prevent HS). The term "treatment" or "treat" is defined herein as the application or administration of LOU064 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing LOU064 or a pharmaceutically acceptable salt thereof, to a subject or an isolated tissue or cell line from a subject, wherein the subject suffers from a specific disease (e.g., HS), has symptoms associated with the disease (e.g., HS symptoms), or has a predisposition to the disease (if applicable), wherein the aim is to cure the disease (if applicable), reduce the severity of the disease, alleviate or improve one or more symptoms of the disease, improve the disease, reduce or improve any associated symptoms of the disease, or predisposition to the disease. The term "treatment" includes treating a subject suspected of having a disease as well as a subject who has a disease or has been diagnosed with a disease or medical condition. In some aspects, the term "treatment" refers to improving a disease or disorder (i.e., slowing or halting or alleviating the development or progression of a disease or at least one of its clinical symptoms). In another embodiment, "treatment" refers to reducing or improving at least one bodily parameter, including those that cannot be identified by the patient. In yet another embodiment, "treat, treating, or treatment" refers to regulating a disease or disorder in a physical (e.g., stabilization of identifiable symptoms) or physiological (e.g., stabilization of bodily parameters) manner, or both. More specifically, the term "treat" disease HS refers to treating inflammatory lesions in a patient with HS (in terms of quantity or quality, or reduction in their volume and size), and / or treating abscesses and inflammatory nodules and / or draining fistulas in a patient with HS, and / or reducing the amount of scar formation and / or alleviating functional limitations associated with scar formation. Treating disease HS also refers to alleviating pain, fatigue, and / or itching associated with HS, reducing purulent discharge and reducing odor associated with purulent discharge, and / or improving the quality of life and / or reducing work-related impairments in patients with HS. As used herein, the term "prevention, prevent, preventing" for a disease or disorder (HS) refers to preventive treatment of the disease or disorder; or delaying and / or inhibiting the onset or progression of the disease or disorder. More specifically, the term "preventing" a disease HS refers to preventing HS lumps and / or the appearance of new lesions; preventing scar formation and preventing functional limitations associated with scar formation; and / or particularly preventing surgical interventions for HS. As used in this article, the phrase "subject population" refers to a group of subjects who will benefit from this treatment in terms of biology, medicine, or quality of life. As used herein, the term "subject" refers to an animal. Typically, an animal is a mammal. "Subject" also refers to, for example, primates (e.g., humans, males or females), cattle, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds, etc. In some embodiments, the subject is a primate. In a preferred embodiment, the subject is a human. When referring to a human, the terms "subject" and "patient" are used interchangeably. As used herein, the phrases "not previously treated with systemic therapy" and "treatment-naïve" refer to HS patients who have not previously received systemic therapy (e.g., methotrexate, cyclosporine), or biologics (e.g., IL-12 and IL-23 blockers, such as uterotumab and gusecubitumab), or TNF-α inhibitors (e.g., adalimumab or infliximab), or IL-17 blockers (e.g., secukinumab, exegizumab, and buprolimab). Systemic agents (i.e., agents administered orally, by injection, etc.) differ from topical agents (e.g., topical medications and phototherapy) in that systemic agents have a systemic (systemic) effect when delivered to the patient. In some embodiments of the disclosed methods, protocols, uses, kits, and pharmaceutical compositions, the patient has not previously received systemic therapy for HS. As used herein, the phrase "previously treated with systemic agents for HS" refers to a patient who has previously received systemic treatment for HS. Such patients include those previously treated with biologics (such as IL-12 and IL-23 blockers, such as uterotumab and gusecubitumab), TNF-α inhibitors (such as infliximab), or IL-17 blockers (such as secukinumab, exegizilumab, and buprolumab), as well as those previously treated with non-biologics, such as systemic immunosuppressants or immunomodulators (e.g., cyclosporine, methotrexate, and cyclophosphamide), or with systemic therapies (including rhodopsin analogues (such as isomorphic rhodopsin), diamine benzoate, metformin, and oral zinc). In some embodiments disclosed herein, the patient has previously received systemic medication for HS. In some implementations, the patient has previously received systemic medication for HS (e.g., methotrexate, cyclosporine), but has not previously received systemic biologics (i.e., drugs produced by a living organism, such as antibodies, receptor decoys, etc.) for HS (e.g., secukinumab, uteroclosab, exegizumab, buprofen, TNF α inhibitors (etanercept, adalimumab, infliximab (Remicade) etc.). In this case, the patient is referred to as "biologic-naïve." In some implementations, the patient is biologically-naïve. As used herein, the terms "selecting" and "selected" in relation to a patient refer to a specific patient selected from a larger patient population based on predetermined criteria. Similarly, "selective treatment" refers to providing treatment to a patient with a specific disease, where this patient is specifically selected from a larger patient group based on predetermined criteria. Likewise, "selective administration" refers to administering medication to a patient specifically selected from a larger patient group based on predetermined criteria. Selection, selective treatment, and selective administration mean delivering personalized therapy to a patient based on their individual medical history (e.g., previous treatment interventions, such as previous treatment with biologics), biological characteristics (e.g., specific genetic markers), and / or presentation (e.g., failure to meet specific diagnostic criteria), rather than simply delivering a standard treatment regimen based on the patient's membership in a larger group. Referring to treatment methods as used herein, selection does not refer to incidental treatment of a patient with specific criteria, but rather to the intentional selection of a patient to receive treatment based on specific criteria. Therefore, selective treatment / administration differs from standard treatment / administration, which delivers a specific drug to all patients with a specific disease, regardless of their personal medical history, disease presentation, and / or biological characteristics. In some implementations, patients are selected for treatment based on the presence of HS. As used herein, the terms "a / an", "the", and similar terms used in the context of this invention (especially in the context of a claim) should be interpreted to cover both the singular and the plural, unless otherwise stated herein or clearly contradicted by the context. As used herein, the term "pharmaceutical composition" refers to a product obtained by using or mixing or combining one or more active ingredients. It should be understood that, as used herein, pharmaceutical composition includes both fixed and non-fixed combinations of active ingredients. The term "fixed combination" refers to the simultaneous administration of an active ingredient, such as a compound having formula (I) or a pharmaceutically acceptable salt thereof, and one or more combination partners, as a single entity or dosage form to a patient. In this case, the term refers to a fixed-dose combination within a unit dosage form (e.g., capsule, tablet, or sachet). The terms "non-fixed combination" or "kit of parts" both indicate that such active ingredients, such as the compounds disclosed herein, and one or more combination partners and / or one or more adjuvants, are administered simultaneously, concurrently, or sequentially without specific time constraints, or independently, to a patient, wherein such administration provides therapeutically effective levels of both compounds in the patient, particularly where such time intervals allow for effective doses of the combination partners to exhibit synergistic effects (e.g., additive or synergistic effects). The term "non-fixed combination" also applies to mixture therapies, such as the administration of three or more active ingredients. Therefore, the term "non-fixed combination" is specifically defined as a dosing, use, composition, or formulation in the sense that the compounds described herein can be administered independently of each other (i.e., simultaneously or at different times). It should be understood that the term "non-fixed combination" also includes the use of a single agent with one or more fixed combination products, wherein each independent formulation has a different amount of the active ingredient. It should be further understood that the combination products described herein and the term "non-fixed combination" encompass active ingredients (including the compounds described herein), wherein such combination partners are administered in completely separate pharmaceutical dosage forms or formulations sold independently of each other. Instructions for use of the non-fixed combination are provided or may be provided in the packaging (e.g., leaflets) or other information provided to physicians and / or healthcare professionals. The independent formulations or portions of such formulations, products, or compositions may then be administered simultaneously or sequentially, i.e., the portions of a kit may be administered at different times and / or any portion of a kit may be administered at the same or different time intervals. Specifically, the selected dosing intervals ensure that the combined use of these components is more effective than / exceeds the effect of using a compound having formula (I) or a pharmaceutically acceptable salt thereof alone for treating the disease; therefore, the compounds used in the drug combinations described herein have synergistic activity. The total amount of the compound having formula (I) or a pharmaceutically acceptable salt thereof, or the ratio of the second agent to be administered as part of the drug combination, can be changed or adjusted to better meet the needs of a specific patient subgroup or an individual patient, which may be due to factors such as the patient's age, sex, weight, etc. As used herein, the terms “co-administered” or “combination administered” are intended to cover administering one or more of the compounds described herein together with a selected combination partner to a single subject (e.g., a patient or subject) in need, and are intended to include treatment regimens in which such compounds are not necessarily administered via the same route of administration and / or administered simultaneously. LOU064 LOU064 (= N-(3-(6-amino-5-(2-(N-methacrylamino)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzoamide, INN: ramibrutinib) was disclosed as a drug candidate in WO 2015 / 079417 A1 for the selective inhibition of Bruton's tyrosine kinase. This compound is a potent, highly selective, and irreversible covalent BTK inhibitor. Due to its binding to the inactive conformation of BTK, LOU064 exhibits precise kinase selectivity and thus reduces off-target kinase binding. Furthermore, due to covalent inhibition, the compound exhibits potent and sustained pharmacodynamic effects without the need for prolonged and high systemic compound exposure (Angst, D. et al., Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase, J Med Chem. 2020 May 28; 63(10):5102-5118). The LOU064-based free base used in the method of this invention is represented by formula (I): (I). In other embodiments, N-(3-(6-amino-5-(2-(N-methacrylamino)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzoamide is a free base in anhydrous crystalline form A, as disclosed in WO 2020 / 234779 (Example 1), which is hereby incorporated by reference. LOU064, which has previously been recommended for the treatment of chronic spontaneous urticaria (CSU) (WO 2020 / 234782 A1) and Sjögren's syndrome (SjS) (WO 2020 / 234781 A1), is currently being tested in Phase II clinical trials for CSU and SjS. In WO 2020 / 234782 A1, it is generally recommended to administer 10 mg, 25 mg and 100 mg twice daily to achieve maximum efficacy in CSU. In a phase 2b, randomized, double-blind, placebo-controlled trial, the efficacy of LOU064 against H over 12 weeks was evaluated. 1. Efficacy and safety of LOU064 in patients with at least moderately active chronic spontaneous urticaria (CSU) whose condition was not adequately controlled by antihistamines. Patients received LOU064 at 10 mg once daily, 35 mg once daily, 100 mg once daily, 10 mg twice daily, 25 mg twice daily, 100 mg twice daily, or placebo (1:1:1:1:1:1:1 ratio). The 25 mg twice daily regimen was found to be particularly effective compared to other doses. Therefore, a dose of 25 mg bid was chosen for the subsequent Phase III clinical study of CSU. The reported BTK occupancy rate in blood and / or tissues is an appropriate biomarker for the doses selected in clinical studies (such as the CSU and SjS studies) (WO 2020 / 234782 and WO 2020 / 234781). In addition, it has been reported that the BTK occupancy rate and duration of BTK occupancy differ in the blood and various tissues of female rats (WO 2020 / 234781). BTK occupancy rates in different tissues are associated with efficacy and optimal dose selection for different indications. However, there is currently no consistent overview of all tissues relevant to HS indications, thus requiring penetration into one or more tissues for the treatment or prevention of HS. As reported in rats, BTK occupancy rates and BTK occupancy half-lives differ in blood and various tissues. BTK occupancy half-life depends on the turnover rate (BTK's ability to regenerate cells). This turnover rate varies in each tissue and is species-specific. BTK occupancy further depends on the compound's PK / PD properties, which are also species-dependent. BTK inhibitors can exert their effects or intervene through three basic mechanisms or pathways: 1) reducing allergic / type I hypersensitivity reactions via FcγR1; 2) inhibiting B cell autoreactivity and immune complexes in autoreactive / inflammatory or type 3 hypersensitivity reactions via FcγR and / or BCR; and 3) inhibiting autoantibody secretion in autoantibody pathology or type 2 hypersensitivity reactions via BCR. Without theoretical correlation, BTK inhibition is associated with the latter two pathways, as HS is thought to be related to B cell activity (Rumberger et al. 2020, Gudjonsson et al.) and through the presence of autoantibodies (Byrd et al. (2018)). J. Dermatol. [British Journal of Dermatology]; 179(3):792-794, (2019), Camona-Rivera et al. (2021) J Invest Dermatol. [Journal of Dermatological Research] Oct 1:S0022-202X(21)02286-7. doi: 10.1016 / j.jid.2021.07.187). B cells and plasma cells can be found in the tertiary lymphoid organs of the lesion tissue. Compared with skin mast cells, B cells in the tertiary lymphoid organs of HS lesions may have higher BTK conversion, and due to fibrotic tissue remodeling as well as abscesses and fistulas, adequate target tissue penetration may be more difficult to achieve in HS compared with CSU. On the other hand, CSU may rely particularly on the first pathway mentioned above, as demonstrated by the activity of anti-IgE antibodies (via FcɛR1), and therefore, any dose disclosed for CSU or other indications may not be expected to produce a clinical response to HS. Therefore, without being bound by any theory, the effective dose of LOU064 for the treatment or prevention of HS is a dose that allows for higher tissue concentrations into inflamed, partially fibrotic HS lesions and has the potential for higher BTK conversion. Pharmaceutical components used in the method of the present invention When combined with a pharmaceutically acceptable carrier, a BTK inhibitor, i.e., a compound having formula (I) or a pharmaceutically acceptable salt thereof, can be used as a pharmaceutical composition. In addition to a compound having formula (I) or a pharmaceutically acceptable salt thereof, such a composition may also include a carrier, various diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials known in the art. The characteristics of the carrier depend on the route of administration. Pharmaceutical compositions used in the disclosed methods may also contain other therapeutic agents for treating specific targeting disorders. For example, the pharmaceutical composition may also include anti-inflammatory or antipruritic agents. Such additional factors and / or agents may be included in the pharmaceutical composition to synergize with a compound having formula (I) or a pharmaceutically acceptable salt thereof, or to minimize side effects caused by a compound having formula (I) or a pharmaceutically acceptable salt thereof. In a preferred embodiment, the pharmaceutical composition used in the disclosed methods comprises a compound having formula (I) or a pharmaceutically acceptable salt thereof, at a daily dose of about 50 mg to 200 mg, for example, 25 mg bid or 100 mg bid. Suitable compositions for oral administration include effective amounts of the compounds of the present invention in the form of tablets, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use are prepared according to any method known in the art for manufacturing pharmaceutical compositions, and such compositions may contain one or more agents selected from the group consisting of sweeteners, flavoring agents, coloring agents, and preservatives to provide a pharmaceutically refined and palatable formulation. Tablets may contain the active ingredient mixed with non-toxic, pharmaceutically acceptable excipients suitable for manufacturing tablets. These excipients are, for example, inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate, or sodium phosphate; granulating and disintegrants such as corn starch or alginic acid; binders such as starch, gelatin, or gum arabic; and lubricants such as magnesium stearate, stearic acid, or talc. Tablets are either uncoated or coated using known techniques to delay disintegration and absorption in the gastrointestinal tract, thereby providing sustained action over a longer period of time. For example, time-delaying materials such as glyceryl monostearate or glyceryl distearate can be used. Formulations for oral use can be presented as hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent (e.g., calcium carbonate, calcium phosphate, or kaolin), or as soft gelatin capsules in which the active ingredient is mixed with an aqueous or oily medium (e.g., peanut oil, liquid paraffin, or olive oil). The pharmaceutical composition used in the disclosed methods can be prepared in a conventional manner. In one embodiment, the pharmaceutical composition is provided for oral administration. For example, such pharmaceutical compositions are tablets or gelatin capsules comprising an active ingredient and the following: a) a diluent, such as lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, and / or glycine; b) a lubricant, such as silica, talc, stearic acid, its magnesium or calcium salt, and / or polyethylene glycol; and, in the case of tablets, c) a binder, such as magnesium aluminum silicate, starch paste, gelatin, tragacanth gum, methylcellulose, sodium carboxymethyl cellulose, and / or polyvinylpyrrolidone; and, if desired, d) a disintegrant, such as starch, agar, alginate, or its sodium salt or effervescent mixture; and / or e) an adsorbent, colorant, flavoring agent, and sweetener. Therefore, the pharmaceutical composition used in the method of the present invention comprises LOU064 and one or more pharmaceutically acceptable carriers, each of which is independently selected from fillers, lubricants, binders, disintegrants, and flow aids. In another embodiment, the suitable pharmaceutical composition, LOU064, can be present in any pharmaceutically acceptable form. Preferably, the pharmaceutical composition is in tablet or capsule form. Tablets can be film-coated or enteric-coated according to methods known in the art. It is also preferable that LOU064 included in the pharmaceutical formulation / composition is a nano- or micron-sized particle. If LOU064 exists in the form of nanoparticles in the pharmaceutical formulation, the average particle size can be less than 1000 nm. Preferably, the average particle size of LOU064 can be less than 500 nm, and more preferably less than 250 nm. In a preferred embodiment, the average particle size of LOU064 may be between about 50 nm and about 1000 nm, or between about 50 nm and about 750 nm, or between about 60 nm and about 500 nm, or between about 70 nm and about 350 nm, or between about 100 nm and about 170 nm. More preferably, the average particle size of LOU064 may be between about 100 nm and about 350 nm, or between about 110 nm and about 200 nm, or between about 120 nm and about 180 nm, or between about 120 nm and about 160 nm. More preferably, the average particle size of LOU064 may be between about 150 nm and about 200 nm. If LOU064 is present in the form of nanoparticles in the pharmaceutical formulation, oral administration is preferably at a dose of about 25 mg to about 100 mg twice daily, more preferably at a dose of about 100 mg twice daily. If LOU064 exists in the pharmaceutical formulation as micron-sized particles, the average particle size may be 1–5 µm or preferably 1.0–1.5 µm. More preferably, the average particle size of LOU064 may be 1.1 to 1.3 µm. If LOU064 is present in the form of micron-sized particles in the pharmaceutical formulation, oral administration is preferably at a dose of about 25 mg to about 100 mg twice daily, for example, at a dose of about 25 mg twice daily. In a preferred embodiment, the polydispersity index (PI) is between 0.01 and 0.5, more preferably between 0.1 and 0.2, and particularly between 0.12 and 0.14. The preferred particle size distribution is shown in Figure 5. The average particle size described above is intensity-weighted. The average particle size can be determined by dynamic light scattering. Preferably, the average particle size is determined by photon correlation spectroscopy (PCS). In particular, the Zetasizer Nano ZS version 7.13 from Malvern Panalytical Ltd., UK, can be used to determine the average particle size. Preferably, the measurement is performed using a 0.1 mM NaCl solution in purified water (1:10) as a wet dispersion method, with an attenuation index of 2–9, particularly 5. The measurement is preferably performed at 25°C. Other preferred settings for the measurement system are as follows: Cuvette: Disposable quantitative cuvette; Counting rate (kcPs): 315; Duration: 60 sec; Measurement position (mm): 4.65. In one embodiment of the present invention, the LOU064 composition is formulated into a pharmaceutical composition suitable for oral administration to humans according to conventional procedures. Typically, the composition for oral administration is in the form of capsules or tablets. In one embodiment, the pharmaceutical composition / formulation of LOU064 may be formulated according to the formulation disclosed in U.S. Application No. 63 / 141558 or a member of its family (published PCT WO 2022 / 162513), which is incorporated herein by reference. According to the present invention, a suitable pharmaceutical composition for oral administration comprises LOU064 and a binder. Suitable adhesives include polyvinylpyrrolidone-vinyl acetate copolymers, polyvinylpyrrolidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose, carboxymethyl cellulose, methylcellulose, hydroxyethyl cellulose, carboxyethyl cellulose, carboxymethyl hydroxyethyl cellulose, polyethylene glycol, polyvinyl alcohol, shellac, polyvinyl alcohol-polyethylene glycol copolymers, polyethylene glycol-propylene glycol copolymers, or mixtures thereof. Preferably, the adhesive is a polyvinylpyrrolidone-vinyl acetate copolymer. The weight ratio of LOU064 to the adhesive can be from about 3:1 to about 1:3; for example, about 3:1, about 2:1, about 1:1, preferably about 2:1 or about 1:1. Preferably, the suitable drug composition for oral administration includes LOU064, a binder, and a surfactant. Suitable surfactants include sodium dodecyl sulfate, potassium dodecyl sulfate, ammonium dodecyl sulfate, sodium dodecyl ether sulfate, polysorbate, perfluorobutane sulfonate, dioctyl sulfosuccinate, or mixtures thereof. Preferably, the surfactant is sodium dodecyl sulfate. The weight ratio of LOU064, adhesive, and surfactant is approximately 2:1:0.5, or approximately 2:1:0.1, or approximately 2:1:0.08, or approximately 2:1:0.05, or approximately 2:1:0.04, or approximately 2:1:0.03, or approximately 2:1:0.02. Preferably, the weight ratio of LOU064, adhesive, and surfactant is approximately 2:1:0.08 or approximately 1:1:0.05. In a particularly preferred embodiment, the suitable pharmaceutical composition for oral administration comprises LOU064, a binder, and a surfactant, wherein the binder is a polyvinylpyrrolidone-vinyl acetate copolymer (copovidone), and the surfactant is sodium dodecyl sulfate (SLS), and wherein the weight ratio of LOU064, copovidone, and SLS is approximately 2:1:0.08. Furthermore, it is particularly preferred that LOU064 is present in the pharmaceutical composition in the form of nanoparticles, preferably having an average particle size between approximately 100 nm and approximately 200 nm as measured by PCS. use LOU064 or its pharmaceutically acceptable salts or its crystalline form for treatment or prevention HS The method. Methods for treating or preventing HS with LOU064 or a pharmaceutically acceptable salt thereof are disclosed herein, comprising administering a therapeutically effective dose of LOU064 or a pharmaceutically acceptable salt thereof to the subject. The LOU064 or a pharmaceutically acceptable salt thereof used in the disclosed methods may be administered in vitro, ex vivo, or incorporated into a pharmaceutical composition and administered in vivo to treat patients with HS (e.g., human patients). The appropriate dosage will vary depending on factors such as the specific pharmaceutically acceptable salt of LOU064, the specific polymorphic form of LOU064, the patient's weight, the method of administration, the drug composition, the nature and severity of the condition being treated, and the nature of any prior treatments received by the subject. Ultimately, the attending healthcare provider will determine the amount of LOU064 to be used to treat each individual subject. In some implementations, the attending healthcare provider may administer a low dose of LOU064 and observe the patient's response. In one embodiment of this disclosure, LOU064 or a pharmaceutically acceptable salt thereof is administered orally at a dose of about 50 mg to about 200 mg daily. In one embodiment of this disclosure, LOU064 or a pharmaceutically acceptable salt thereof is administered orally at a dose of about 25 mg twice daily to about 100 mg twice daily, such as about 25 mg twice daily (BID), about 50 mg BID, or about 100 mg BID. In another embodiment, LOU064 is administered orally twice daily at a dose of approximately 25 mg. In another embodiment, LOU064 is administered orally twice daily at a dose of approximately 100 mg. The duration of therapy using the pharmaceutical composition disclosed herein will vary depending on the severity of the disease or disorder being treated and the symptoms and individual response of each subject. In some embodiments, LOU064 is administered to the subject for a short period of time, such as up to 1 week, up to 2 weeks, up to 4 weeks, up to 12 weeks, up to 16 weeks, or up to 24 weeks. In some other embodiments, it is preferred to administer LOU064 to the subject long-term (e.g., unlimited use of LOU064 for the total duration, as long as the disease exists), for example, at least 6 months, or for more than 1, 2, 3, 4, or 10 years. LOU064 or a pharmaceutically acceptable salt thereof may be used for up to 5, 10, 15, 20 years or for life. In a preferred embodiment, the treatment with LOU064 according to the invention is a chronic treatment. HS is a chronic, inflammatory, scarring condition that primarily affects the axillary, groin, under-breast, genital, anal, and perineal areas. It is also known as reverse acne. Three diagnostic criteria define HS: typical lesions (deep, painful nodular [blind] boils in early primary lesions, or abscesses, sinus drainages, bridging scars, and "tombstone" open comedones in secondary lesions); typical distribution (axillary, groin, genital, perineal, and perianal areas, buttocks, and under-breast and inframammary regions); and chronicity and recurrence (Margesson and Danby (2014) Best Practices and Res. Clin. Ob. And Gyn [Clinical Obstetrics and Gynecology Best Practices and Research] 28:1013-1027). The physical extent of HS can be classified using Hurley's clinical staging system, as follows: surface As shown in Figure 1: [ surface 1] : Hurley staging of HS. In fact, a patient with Hurley stage III may have exhausted stage III disease, but still have active stage I or II lesions. HS consists of follicular blockage, duct rupture, and secondary inflammation. Patients initially experience blockage of the follicular duct, which over time leads to duct leakage and horizontal rupture into the dermis. When follicular-pilular-sebaceous (FPSB) repair fails, follicular fragments stimulate three responses, thus initiating the HS course. The first is an inflammatory response triggered by the innate immune system, causing suppuration and tissue destruction, leading to a foreign body reaction and extensive scarring. The second response results in epithelialized sinuses, which may develop from stem cells derived from FPSB units that survive the destruction caused by the inflammatory response. The third, in most cases, produces invasive proliferative gel clusters composed of gels containing inflammatory cells and presumably precursors to the aforementioned epithelialized elements (see Margesson and Danby (2014)). As used herein, the phrase "slowing the progression of HS" refers to reducing the rate of progression of any aspect of the aforementioned HS course, particularly the inflammatory response. In some embodiments of this disclosure, treatment with LOU064 slows the progression of HS. Recurrence of HS in patients includes the development of papules, pustules or inflammatory nodules, pain and itching, abscesses, drainage, and any combination thereof. As used herein, “HS red mass” (etc.) is defined as an increase of at least 25% in the abscess and inflammatory nodule count (AN) relative to baseline, with a minimum increase of two ANs. In some embodiments of this disclosure, treatment with LOU064 according to the disclosed method prevents HS erythema, reduces the severity of HS erythema, and / or reduces the frequency of HS erythema. In some embodiments, when treating a HS patient population according to the disclosed method, less than 5%, less than 10%, less than 15%, or less than 20% experience erythema during the first 16 weeks of treatment. As used herein, phrases such as "reduce the severity of HS redness" indicate a reduction in the intensity of HS redness, such as reducing the number and / or size of abscesses and / or inflammatory nodules, reducing the intensity of specific redness components (e.g., reducing the number, size, thickness, etc. of abscesses and / or inflammatory nodules, reducing the degree of skin irritation (itching, pain), etc.), and / or reducing the duration of the redness (or its components). As used in this article, phrases such as "reducing the frequency of HS lumps" indicate a reduction in the incidence of HS lumps, for example, a reduction in the incidence of abscesses and / or inflammatory nodules. By reducing the frequency of HS lumps, patients will experience fewer HS recurrences. The incidence of lumps can be assessed by monitoring patients over time to determine whether the prevalence of lumps has decreased. As used herein, the phrase "preventing HS erythema" means eliminating future HS erythema and / or erythema components. The effectiveness of HS treatment can be assessed using a variety of known methods and tools for measuring HS disease status and / or HS clinical response. Some examples include, for instance, the Hurley staging system, the Severity Assessment and Rating System (SAHS), the Sartorius score, the modified Sartorius score, the HS Physician Overall Assessment (HS-PGA) score, the Visual Analogue Scale (VAS) or the Numerical Rating Scale (NRS) for assessing skin-related pain or pruritus, the Dermatology Quality of Life Index (DLQI), the HS Clinical Response Based on the Sum of Abscesses and Inflammatory Nodules (HiSCR: HiSCR50, HiSCR75, or HiSCR90), the simplified HiSCR, the EuroQuol-5D (EQ5D), the Hospital Anxiety and Depression Scale, healthcare resource utilization, the Severity Index of Hidradenitis Suppurative (HSSI), the Work Performance Index (WPI), the Inflamed Body Surface Area (BSA), the Acne Inverse Severity Index (AISI), etc. (see, for example, Deckers and Prens (2016) Drugs 76:215-229; Sartorius et al. (2009) Br.). J. Dermatol [British Journal of Dermatology] 161:831-39; Chiricozzi et al. (2015) Wounds [Wounds] 27(10):258-264). In some embodiments, the effectiveness of the methods of the present invention disclosed herein can be assessed by the following: HS Physician Overall Assessment (HS-PGA), Severity Assessment Score (SAHS), Numerical Rating Scale (NRS) (itching or pain), Dermatology Quality of Life Index (DLQI), HS clinical response based on the sum of abscesses and inflammatory nodules (HiSCR i.e., HiSCR50, HiSCR75 or HiSCR90), and / or simplified HiSCR. Preferably, the effectiveness of HS treatment as disclosed herein can be assessed by the following: HS clinical response based on the sum of abscesses and inflammatory nodules (HiSCR i.e., HiSCR50, HiSCR75 or HiSCR90), and / or simplified HiSCR. In some implementations, HS patients respond to HS treatment, achieving HiSCR. In some implementations, when the HS patient population is treated according to the disclosed method, by week 16, at least 30%, at least 40%, at least 50%, at least 60%, or at least 70% achieve at least one of the following: - HiSCR50; - HiSCR75; - HiSCR90; or - simplified HiSCR (sHiSCR); preferably 2HiSCR. In other embodiments, the effectiveness of HS treatment as disclosed herein can be measured by the difference between the response rate of treated patients (i.e., patients who achieved a HiSCR response (HiSCR is HiSCR50, HiSCR75, HiSCR90, or sHiSCR response)) and the response rate of patients treated with placebo by week 16 of treatment. In some embodiments, such difference in response rate, as measured by HiSCR (HiSCR50, HiSCR75, HiSCR90, or sHiSCR), is at least 15%, at least 25%, at least 30%, or at least 35%. For treatment response, preferred scoring systems include HiSCR (HiSCR50, HiSCR75, or HiSCR90), Simplified HiSCR, NRS for pain or pruritus (e.g., NRS30 for pain or NRS30 for pruritus), Severity Assessment Scoring System (SAHS), HS-PGA, inflammatory lesion count (count of abscesses, inflammatory nodules, and / or draining fistulas), ISH4, and DLQI. The Histomachic Rhizoma Clinical Response (HiSCR) is a measure of the clinical response to treatment of HS. The HiSCR50 response to treatment (compared to baseline) is as follows: 1) a reduction of at least 50% in abscesses and inflammatory nodules (AN50), 2) no increase in the number of abscesses, and 3) no increase in the number of draining fistulas. In some implementations, HS patients respond to HS treatment, achieving HiSCR50. In some implementations, when the HS patient population is treated according to the disclosed method, at least 40%, at least 50%, at least 60%, or at least 70% of patients achieve HiSCR50 by week 16 of treatment. As used herein, "simplified HiSCR" or "sHiSCR" refers to a modified HiSCR that excludes abscess counts (relative to baseline) when assessing lesion progression. In a preferred embodiment, simplified HiSCR is achieved when HS patients respond to HS treatment. In some embodiments, when the HS patient population is treated according to the disclosed methods, simplified HiSCR is achieved in at least 40%, at least 50%, at least 60%, or at least 70% of patients by week 16 of treatment. The HiSCR75 response to treatment (compared to baseline) was as follows: 1) a reduction of at least 75% in abscesses and inflammatory nodules, and 2) no increase in the number of abscesses, and 3) no increase in the number of draining fistulas. The HiSCR90 response to treatment (compared to baseline) was as follows: 1) a reduction of at least 90% in abscesses and inflammatory nodules, and 2) no increase in the number of abscesses, and 3) no increase in the number of draining fistulas. In a preferred embodiment, the HS patient responds to HS treatment, achieving HiSCR75 or HiSCR90. In some implementations, when the HS patient population is treated according to the disclosed method, at least 40%, at least 50%, at least 60%, or at least 70% of patients achieve HiSCR75 by week 16 of treatment. In some implementations, when the HS patient population is treated according to the disclosed method, at least 40%, at least 50%, at least 60%, or at least 70% of patients achieve HiSCR90 by week 16 of treatment. Pain can be assessed using a digital rating scale (NRS). In some embodiments, HS patients respond to HS treatment, achieving an improved pain NRS. Pain NRS30 is defined as a reduction of at least 30% and at least 1 unit in pain on the Patient Overall Assessment (PGA) of skin pain compared to baseline in patients with a baseline score of 3 or higher. In some embodiments, HS patients respond to HS treatment, achieving NRS30. In some embodiments, when treating a population of HS patients according to the disclosed method, at least 25%, at least 30%, at least 40%, at least 50%, or at least 60% achieve NRS30 by week 16 of treatment. In a preferred aspect of this embodiment, when treating a population of HS patients according to the disclosed method, at least 30% achieve NRS30 by week 16 of treatment. In some embodiments, in response to treatment according to the claimed method, the patient experiences pain reduction (e.g., by means of VAS or NRS, preferably measured by NRS) as early as 1 or 2 weeks after initial administration. The Severity Assessment Scoring System (SAHS) was described by Hassam et al. JAMA Dermatol (2018), 154(3): 330-335. The severity of HS can be assessed using the SAHS score, and the following criteria were investigated: the number of affected areas (left axilla, right axilla, left submammary, right submammary, breast or chest, abdomen, mons pubis, left groin, right groin, genitals, perianal or perineum, left gluteal muscles, right gluteal muscles, etc. [e.g., neck, behind the ear]), the number of inflammatory and / or painful lesions other than fistulas (ILOF), and the number of fistulas. These physician-assessed items were completed using two patient-reported items: asking patients about the number of new or existing boils or carbuncles that had appeared in the past 4 weeks, and assessing the current pain severity (NRS) of the most symptomatic lesion during daily activities (e.g., sitting, moving, or working) on ​​a numerical rating scale. The SAHS score is a composite score of all the information collected above. Mild HS is defined as a SASH score of 4 or lower. Moderate HS is defined as a SASH score of 5 to 8, and severe HS is defined as a SASH score of 9 or higher. In some implementations, the HS patient responds to HS treatment, achieving an improved SAHS score. In some implementations, the HS patient responds to HS treatment, achieving a reduction of at least one point in the SAHS score compared to baseline. In other implementations, the HS patient responds to HS treatment, achieving a reduction of at least two points or at least three points in the SAHS score compared to baseline. Preferably, the SAHS score was at least 4 at baseline prior to treatment with LOU064. The International Hidradenitis Severity Score (IHS4) is a clinically validated tool for dynamically assessing the severity of HS and can be used in clinical trials or in real-world settings (Zouboulis et al. (2017)). Br. J. Dermatol. [British Journal of Dermatology] ;177(5): 1401-9.). According to this tool, the severity of HS is assessed by summing individual HS lesions according to the following scheme: number of nodules × 1 + number of abscesses × 2 + number of drainage tunnels (fistulas / sinuses) × 4. Then the severity of HS is defined as: Mild HS: ≤ 3 points; Moderate HS: 4–10 points; Severe HS: ≥ 11 points. HS lesions are defined as follows: Nodules (inflammatory nodules) are raised, three-dimensional, round, infiltrative lesions with a diameter > 10 mm. Abscesses are tender but fluctuating masses with a diameter > 10 mm and a surrounding erythematous area; pus is present in the center of the abscess. Drainage tunnels are raised, tender but fluctuating longitudinal masses of varying length and depth, terminating at the skin surface, and sometimes exuding fluid. Fistulas and sinuses are examples of tunnels. In some implementations, HS patients achieve an improved IHS4 score (i.e., a reduction). In some implementations, the HS patient responds to HS treatment, achieving a reduction of at least two points in the IHS4 score compared to baseline. In other implementations, the HS patient responds to HS treatment, achieving a reduction of at least three or four points in the IHS4 score compared to baseline. The DLQI is the most mature quality of life assessment tool for dermatological patients. It consists of questions about the impact of the skin condition on various aspects of sensation and daily living activities over the past week. Each question is scored from 0 (no impact at all) to 3 (very high). The highest score is 30 points, where 0–1 is considered no impact on the patient's life, 2–5 is a small impact, 6–10 is a moderate impact, 11–20 is a very large impact, and 21–30 is a very large impact. (See Finlay and Khan (1994) Clin Exp Dermatol [Clinical Experimental Dermatology] 19:210–16). In some implementations, patients with HS respond to HS treatment, achieving an improved DLQI. In some embodiments, in response to treatment according to the claimed method, such as by means of a standard CRP assay or a high-sensitivity CRP (hsCRP) assay, the patient experiences a decrease in CRP as early as 1 or 2 weeks after initial administration. As used herein, "C-reactive protein" and "CRP" refer to serum C-reactive protein, a plasma protein commonly used as an indicator of the acute phase response to inflammation. Plasma CRP levels can be given at any concentration, such as mg / dL or nmol / L. CRP levels can be measured by a variety of standard assays, such as radioimmunodiffusion, electroimmunoassay, immunoturbidimetry, ELISA, turbidimetry, fluorescence polarization immunoassay, and laser turbidimetry. CRP testing can be performed using a standard CRP assay or a high-sensitivity CRP (hs-CRP) assay (i.e., a high-sensitivity assay that can measure low levels of CRP in a sample using laser turbidimetry). Kits for testing CRP levels can be purchased from various companies, such as Calbiotech, Inc., Cayman Chemical, Roche Diagnostics Corporation, Abazyme, DADE Behring, Abnova Corporation, Aniara Corporation, Bio-Quant Inc., and Siemens Healthcare Diagnostics. The Sartorius HS score (also known as the HS score or HSS) is derived by counting the affected areas, nodules, and sinus tracts in patients with HS. (Sartorius et al. (2003)) Br J Dermatol [British Journal of Dermatology] 149:211–13). The modified Sartorius HS score is a revised version that makes the original HSS more practical by slightly simplifying it, for example, by including fewer specific lesions in the score and changing the number of scores given for each parameter (Sartorius et al. (2009) Br. J Dermatol. [British Journal of Dermatology] 161:831-839). In some implementations, the improved modified Sartorius HS is achieved by the patient responding to HS treatment. The HS Physician Overall Assessment (HS-PGA) is a 6-point rating scale (scoring from 0 to 5) based on the number of HS lesions (i.e., abscesses, draining fistulas, inflammatory nodules, and non-inflammatory nodules). (Kimball AB, Kerdel F, Adams D et al. Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial). Ann InternMed [Annals of Internal Medicine] 2012; 157: 846–855). In some implementations, HS patients respond to HS treatment, achieving an improved HS-PGA. In some implementations, HS patients respond to HS treatment, achieving a reduction of at least 2 points in the HS-PGA score compared to baseline. Preferably, the HS-PGA score was at least 3 at baseline prior to treatment with LOU064. In some embodiments, when the HS patient population is treated according to the disclosed method, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of patients who responded to treatment by week 16 (e.g., patients who achieved HiSCR (e.g., HiSCR50; HiSCR75 or HiSCR90) or simplified HiSCR by week 16) had a sustained response 3 months, 6 months, or 12 months after the end of treatment. In another embodiment, at least 40% or at least 50% of patients who responded to treatment by week 16 (e.g., patients who achieved HiSCR (e.g., HiSCR50; HiSCR75 or HiSCR90) or simplified HiSCR by week 16) had a sustained response 3 months after the end of treatment. Preferably, at least 70% of patients who responded to treatment by week 16 (e.g., patients who achieved a HiSCR (e.g., HiSCR50; HiSCR75 or HiSCR90) or a simplified HiSCR by week 16) had a sustained response for 3 months after the end of treatment. As used herein, the term "sustainable" means that the outcome or goal (e.g., pain reduction, inflammation reduction) is substantially maintained at a given time. Disease-related pruritus can be assessed through a patient survey. Patients are asked to rate disease-related pruritus on a scale of 0 (no pruritus) to 10 (worse, possibly pruritus). In some implementations, when the HS patient population is treated according to the disclosed method, the pruritus score improves by at least 2 points, preferably by at least 3 points. Furthermore, when compared to the placebo group, the difference between the treatment group and the placebo group is at least 1 point. Lesion-related itching can also be assessed using the Numerical Rating Scale (NRS). The vast majority of HS patients report itching (Fernandez et al. (2021) Itch and pain by lesion morphology in hidradenitis suppurativa patients). Int J Dermatol. [International Journal of Dermatology]; 60(2):e56-e59). The NRS is a segmented numerical version of the Visual Analogue Scale (VAS), in which respondents select an integer (0-10 on an 11-subscale) that best reflects the intensity of their skin disease-related itching (Nguyen et al. (2021)). J Eur Acad Dermatol Venereol. [European Society of Dermatology and Venereology Journal] Jan 2021;35(1):50-61). In some embodiments, HS patients respond to HS treatment, achieving improved skin NRS. Pruritus NRS30 is defined as a reduction of at least 30% in skin pruritus compared to baseline. In some embodiments, HS patients respond to HS treatment, achieving skin NRS30. In some embodiments, when treating a population of HS patients according to the disclosed method, skin NRS30 is achieved by week 16 of treatment in at least 25%, at least 30%, at least 40%, at least 50%, or at least 60% of patients. In a preferred aspect of this embodiment, when treating a population of HS patients according to the disclosed method, skin NRS30 is achieved by week 16 of treatment in at least 30% of patients. In some embodiments, in response to treatment according to the claimed method, the patient experiences a reduction in skin pruritus (as measured by skin NRS) as early as 1 or 2 weeks after initial administration. Odor caused by lesion drainage can be assessed through a patient survey. Patients are asked to rate the odor caused by lesion drainage on a scale of 1 (no odor), 2 (slight odor), 3 (moderate odor), and 4 (heavy odor). In some embodiments, when the HS patient population is treated according to the disclosed method, the pruritus score improves by at least 1 point, preferably by at least 2 points. Furthermore, when compared with the placebo group, the difference between the treatment group and the placebo group is at least 1 point. The impact of pruritus (HS) on work performance can be assessed through a patient survey. Patients are asked to rate the degree to which HS affects their ability to perform work on a scale of 1 (no impact), 2 (some impact), 3 (moderate impact), 4 (significant impact), and 5 (inability to perform any work). In some implementations, when the HS patient population is treated according to the disclosed method, the pruritus score improves by at least 1 point, preferably by at least 2 points. Furthermore, when compared to the placebo group, the difference between the treatment group and the placebo group is at least 1 point. Security: The short-term safety of LOU064 has been demonstrated in a Phase I clinical trial with a single dose of up to 600 mg and further with 100 mg twice daily for up to 18 days. However, no data are available at this time regarding long-term safety (i.e., beyond 52 weeks). Given the dose-limiting side effects observed with the covalently irreversible BTK inhibitors evatinib and tolebutinib, dose-limiting elevations of liver enzymes have been observed with evatinib at a dose of 75 mg bid in phase II clinical studies, and dose-limiting diarrhea with tolebutinib (Becker A. et al., 2019, Clin Transl Sci; 13, 325-336; Montalban X. et al., 2019, N Engl J Med; 380(25): 2406-17, Smith PF et al., 2019, ACTRIMS Forum, February 28, 2019, P072), it is encouraging that even with the extended period (up to 52 weeks) of administration of LOU064 at a higher dose of 100 mg bid, no meaningful increase in the incidence of these adverse events was observed. In particular, over an extended period (up to 52 weeks), LOU064 at a dose of 100 mg twice daily did not induce any dose-limiting increases in liver enzymes or other off-target effects. Therefore, LOU064 is suitable for long-term treatment. Therefore, one object of the present invention is to use LOU064 in the method described herein, wherein the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and lipase at week 12, week 24, or week 52 of treatment change by no more than 10% compared to baseline levels at the start of treatment. Therefore, it is particularly surprising that LOU064 not only treats HS effectively compared to other BTK inhibitors, especially compared to acalabrutinib, particularly when used for extended periods of maintenance therapy, but also exhibits a better safety profile. For example, currently approved BTK inhibitors primarily used to treat hematologic malignancies (ibrutinib, acalabrutinib, and zanubrutinib) have known safety concerns. Major safety concerns include infection, effects on platelet function (risk of bleeding), and cytopenia. Other safety concerns with one or more approved BTKi include arrhythmias (atrial fibrillation and flutter) and, specifically, heart failure and hypertension, only with ibrutinib. Therefore, in a preferred embodiment of the invention, LOU064 or a pharmaceutically acceptable salt thereof used in the treatment of HS is intended for long-term treatment. The term long-term treatment indicates that LOU064 or a pharmaceutically acceptable salt thereof is used for an extended period of time. For example, LOU064 or a pharmaceutically acceptable salt thereof may be safely used for more than 6 months, 10 months, 1 year, 2 years, 3 years, 4 years, or 10 years. LOU064 or a pharmaceutically acceptable salt thereof may be used for up to 2 years, 5 years, 10 years, 15 years, 20 years, or a lifetime. In one implementation, LOU064 not only effectively treats HS but also has safety features including one or more of the following: - no clinically relevant increase in risk of infection, - no clinically relevant increase in severe bleeding, - no clinically relevant increase in liver enzymes; allowing for long-term treatment. combination: The pharmaceutical composition used in the disclosed methods may also contain other therapeutic agents for treating specific targeting disorders. For example, the pharmaceutical composition may also include anti-inflammatory agents. Such additional factors and / or agents may be included in the pharmaceutical composition to produce a synergistic effect with LOU064 described herein. During the treatment of HS, various therapies can be beneficially combined with LOU064. Therefore, LOU064 can be administered simultaneously with one or more other therapeutic agents, or administered before or after the therapeutic agents. LOU064 used in the methods of the present invention can be administered separately via the same or different routes of administration as other pharmaceutical agents, or administered together with them in the same pharmaceutical composition. In one embodiment, the present invention relates to a method for treating or preventing HS in a subject, the method comprising administering to the subject a therapeutically effective dose of LOU064 and at least one other therapeutic agent as a combination formulation for simultaneous, separate, or sequential use in therapy. Where desired, the pharmaceutical composition used in the method of the present invention may comprise pharmaceutically acceptable excipients as described above. Products provided as a combination formulation for use in the methods of the present invention include compositions comprising LOU064 and one or more other therapeutic agents together in the same pharmaceutical composition, or LOU064 and one or more other therapeutic agents in separate forms (e.g., in a set). In one embodiment, the present invention provides a kit for use in the method of the invention, the kit comprising two or more separate pharmaceutical components, at least one of which contains LOU064 or a pharmaceutically acceptable salt thereof. In one embodiment, the kit includes means for separately retaining the components (e.g., containers, separate bottles, or separate foil packs). An example of such a kit is blister packaging, as typically used for packaging tablets, capsules, and the like. The kits of this invention can be used to administer different dosage forms (e.g., oral and parenteral), to administer individual components at different dose intervals, or to titrate individual components together. To aid compliance, the kits of this invention typically include instructions for use for administration. In the combination therapy of the present invention, LOU064 and other therapeutic agents may be manufactured and / or formulated by the same or different manufacturers. Furthermore, LOU064 and another therapeutic agent may be used together to form a combination therapy: (i) before the combination product is released to a physician (e.g., in the case of a kit containing compounds and other therapeutic agents for use in the methods of the present invention); (ii) shortly before administration, by the physician himself (or under the physician's guidance); (iii) in the patient himself, for example during the sequential administration of LOU064 and other therapeutic agents. Therefore, the present invention provides the use of LOU064 or a pharmaceutically acceptable salt thereof for the treatment or prevention of HS, wherein the medicament is prepared for administration in combination with another therapeutic agent. The present invention also provides the use of another therapeutic agent for the treatment or prevention of HS, wherein the medicament is LOU064 or a pharmaceutically acceptable salt thereof administered. The present invention also provides LOU064 or a pharmaceutically acceptable salt thereof for use in methods of treating or preventing HS, wherein the compound is prepared for administration in conjunction with another therapeutic agent. The present invention also provides another therapeutic agent for use in methods of treating or preventing HS, wherein the other therapeutic agent is prepared for administration in conjunction with LOU064 or a pharmaceutically acceptable salt thereof. The present invention also provides LOU064 or a pharmaceutically acceptable salt thereof for use in methods of treating or preventing HS, wherein said compound is administered together with another therapeutic agent. The present invention also provides another therapeutic agent for use in methods of treating or preventing HS, wherein said other therapeutic agent is administered together with LOU064 or a pharmaceutically acceptable salt thereof. The present invention also provides the use of LOU064 or a pharmaceutically acceptable salt thereof for the treatment and / or prevention of HS in patients requiring such treatment and / or prevention, wherein the patient has previously (e.g., within 24 hours) been treated with another therapeutic agent. The present invention also provides the use of another therapeutic agent for the treatment or prevention of HS in patients in need, wherein the patient has previously (e.g., within 24 hours) been treated with LOU064 or a pharmaceutically acceptable salt thereof. Such combination therapies include topical treatments (creams [nonsteroidal or steroidal], lotions, antibacterial agents), systemic treatments (e.g., the use of biologics, antibiotics, or chemicals), antibacterial agents, photodynamic therapy, and surgical interventions (laser, drainage or incision, excision). Examples of oral antibiotics include tetracycline, clindamycin, and rifampin. Non-limiting examples of topical HS agents used in conjunction with LOU064 include benzoyl peroxide, topical steroid creams, topical antibiotics in the aminoglycoside group such as clindamycin, orthopone and erythromycin, resorcinol cream, iodine scrub, and chlorhexidine. Non-limiting examples of HS agents used in conjunction with LOU064 for systemic therapy include IL-17 antagonists (exegizilumab, buprolumab, secukinumab, CJM112), as well as IL-17A / F antagonists (such as imigitizumab) or IL-17C antagonists (such as MOR106), tumor necrosis factor-α (TNF-α) blockers (such as Enbrel® (etanercept), Humira® (adalimumab), Remicade® (infliximab)). Monoclonal antibodies (such as Simponi® and Golimumab), interleukin 12 / 23 blockers (such as Stelara®, tasocitinib, and braginumab), IL-23 blockers (such as gusecurumab, tetragergizumab, and lizangizumab), p19 inhibitors, PDE4 inhibitors (such as apremilast or Otezla® or others such as roflurane), complement pathway inhibitors (such as factor B inhibitors) (e.g., compounds disclosed in WO 2015 / 009616 or LNP023 (also known as 4-((2) S,4 S)-4-ethoxy-1-((5-methoxy-7-methyl)-1 H-indol-4-yl)methyl)piperidin-2-yl)benzoic acid), C5a inhibitors (such as IFX-001 or vilobelimab or CCX168 (also known as avacopan or BDB001), IL-1 antagonists (canaginumab, gevojiizumab, linaccept, anaginex or bemipromazine), or bispecific antibodies (such as MAS825 or rugiizumab (IL-1b and IL-1a)), inflammasome inhibitors (such as NLRP3 and NLRP5 inhibitors), CXCR1 / 2 inhibitors, IL-18 antagonists, IL-6 antagonists, IL-36 antagonists, CD20 antagonists, CTLA4 antagonists, IL-8 antagonists, B cell depletion agents (especially CD20 antagonists, such as rituximab), to And BAFF-R (such as ilimibe) and CD40 antagonists (such as iscalimab (CFZ533)), IL-21 antagonists, IL-22 antagonists, IL-36 or IL-36R antagonists, GCSF inhibitors, VEGF antagonists, CXCL antagonists, MK-2 inhibitors (such as zunsemetinib), IRAK4 inhibitors or IRAK4 degraders (such as SAR44656), LTA4H inhibitors, S1P inhibitors, BTK inhibitors, SYK inhibitors (such as fortaminophen), MMP antagonists, and defensin antagonists (e.g., receptor decoys, antagonistic antibodies, etc.), as well as broad-spectrum oral JAK inhibitors (pan-JAKi) or more specific TYK2 or JAK inhibitors. 1. JAK2 or JAK3 inhibitors (more specific / selective JAK / TYK inhibitors include, for example, allosteric inhibitors (such as deucrayacitinib) or catalytic inhibitors). During HS treatment, other HS agents used in combination with LOU064 include retinoic acid (such as acitretin (e.g., Soriatane® and isotretinoin)), immunosuppressants (e.g., rapamycin, T-cell blockers [e.g., Amevive® (alefacept) and Raptiva® [efalizumab]]), cyclosporine, methotrexate, mycophenolate mofetil, mycophenolic acid, leflunomide, tacrolimus, etc. ), hydroxyurea (e.g., Hydrea®), sulfasalazine, 6-thioguanine, fumarates (e.g., dimethyl fumarate and fumarate), imidazothiopurine, colchicine, cis-retinoic acid, steroids, corticosteroids, certolizumab, mometasone, rosiglitazone, piracetam, botulinum toxin, fluoxetine, IFX-1 (InflaRx), LY-3041658 (Eli Lilly and Company) Lilly), TE-2232 (Immunwork), NSAIDs, COX inhibitors, prescription anesthetics, ketoprofen, codeine, gabapentin, pregabalin, fentanyl, antibiotics (topical, oral, IV) (e.g., clindamycin, rifampin, tetracycline, sarrenzin, deoxytetracycline, minocycline, lysine tetracycline, trimethoprim-sulfamethoxazole, erythromycin, cefaclor, moxifloxacin). Fibrinogen, metronidazole, alone or in combination), corticosteroids (injectable or oral), anti-androgen / hormone therapy (oral contraceptives, spironolactone, finasteride, dutasteride, progesterone IUD, cyproconazole acetate, ethinylestradiol, gestrinone, nifedipine, desogestrel, drospirenone, spironolactone), acetone-concentrated cortisol, MEDI8968, hydroxychloroquine, diamine benzoate, metformin, adapalene, azelaic acid, and zinc. Preferred combinations for use in the disclosed kits, methods and uses include PDE4i and JAKi, as well as antibiotics (all orally). Examples of JAK inhibitors used in combination are BMS986165, INCB054707, rusotetinib, abuxitinib, tofacitinib, and baricitinib. Other examples of JAK inhibitors are compounds disclosed in WO 2017 / 089985, WO 2018 / 055550, and WO 2018 / 055551. Those familiar with this technology will be able to identify the appropriate dosage of the aforementioned HS agent for co-delivery with LOU064. When co-administered with a CYP3A inhibitor, especially a strong CYP3A inhibitor such as a strong CYP3A4 inhibitor, oral exposure to LOU064 is expected to increase several-fold. Similarly, strong inducers of CYP4A (e.g., CYP3A4) can significantly reduce exposure and lead to decreased efficacy of LOU064. These properties of LOU064 are relevant not only to the treatment of HS but also to any BTK-induced condition. Strong CYP3A inhibitors or CYP3A inducers are defined according to FDA 2020 guidance. Therefore, a strong CYP3A inhibitor (e.g., a CYP3A4 inhibitor) is an inhibitor that, compared to LOU064 alone, results in a more than 5-fold increase in area under the curve (AUC) or a more than 80% decrease in clearance when co-administered with LOU064. Strong CYP3A inducers (e.g., strong CYP3A4 inducers) are inducers that, when co-administered with LOU064, reduce AUC by 80% or more (e.g., 85%, 90%, 95%) compared to LOU064 alone. Concomitant administration of strong CYP3A inhibitors and / or inducers (e.g., strong CYP3A4 inhibitors and / or inducers) may cause substantial changes in LOU064 drug exposure and should be avoided. Strong CYP3A4 inhibitors include drugs selected from the following: boprevir, clarithromycin, cobistat, conivatan, danoprevir / ritonavir, derenavir / ritonavir, erteiravir / ritonavir, ederaris, indinavir, indinavir / ritonavir, etoconavir, ketoconazole, LCL161, lopinavir / ritonavir, mibelavidil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, saquinavir / ritonavir, teriprevir, telithromycin, telanavir / ritonavir, acetylenin, dasabuvir sodium (Viekira pack), or / and voriconazole. CYP3A4 inhibitors can also contain grapefruit juice. Therefore, in another preferred embodiment, LOU064 is not administered in conjunction with strong inhibitors and / or inducers of CYP3A4 (e.g., as defined above). Further investigation revealed that LOU064 can be co-administered with oral contraceptives (such as ethinylestradiol or levonorgestrel) without significantly affecting the exposure and efficacy of the oral contraceptives. Therefore, in a preferred embodiment, LOU064 is co-administered with oral contraceptives. As a covalently irreversible BTK inhibitor, LOU064 works by irreversibly inhibiting BTK, which is counteracted by de novo protein synthesis. Therefore, without being bound by any theoretical framework, it is believed that while the remodeling of the B-cell pool following B-cell depletion may take several months, the recovery of B-cell function after BTK inhibition can be achieved shortly after discontinuation, particularly within days. Thus, the therapy can be rapidly discontinued if needed, providing clinicians and patients with a easier and faster response capability in the event of unforeseen circumstances. Especially given the COVID-19 pandemic, patients with B-cell depletion have a higher risk of infection. Furthermore, the lack of a fully functional adaptive immune response may lead to a more severe disease course. However, because LOU064 does not deplete the B-cell pool, discontinuation of therapy leads to a rapid recovery of full B-cell function. This enables patients and treating physicians to respond quickly to infectious diseases or vaccination needs, particularly with live and attenuated vaccines. According to the present invention, LOU064 can be administered during infection (e.g., during COVID-19 infection). Therefore, LOU064 administration can continue during infection (e.g., during COVID-19 infection). Preferably, LOU064 is administered delayed in patients with active infections (such as COVID-19) until the infection subsides. Therefore, one embodiment of the present invention relates to LOU064 for use in the treatment of HS, wherein patients with acute infection or prior infection with COVID-19 are being treated. In another implementation, LOU064 treatment continued during COVID-19 infection. In a preferred embodiment, LOU064 treatment is interrupted during COVID-19 infection and resumed after the infection is overcome. Further embodiments of the invention relate to LOU064 for use in the treatment of HS, wherein the patient is vaccinated during LOU064 therapy. Alternatively, the patient may receive a non-live vaccine during LOU064 therapy. In one embodiment, the patient receives a quadrivalent influenza vaccine, a PPV-23 vaccine, or a KLH neoantigen vaccine during LOU064 therapy (e.g., 15 days after the start of LOU064 therapy). In one aspect of this embodiment, the patient receiving the quadrivalent influenza vaccine achieves a response defined as a >4-fold increase in anti-hemagglutinin antibody titer compared to baseline 28 days after vaccination. In another aspect of this embodiment, the patient receiving the PPV-23 vaccine achieves a >2-fold increase in IgG titer compared to baseline 28 days after vaccination. In yet another embodiment, the patient receiving the KLH neoantigen vaccine achieves a T-cell-dependent antibody response, as measured by anti-KLH IgG and IgM titers, 28 days after vaccination. Another embodiment of the invention relates to LOU064 for use in the treatment of HS, wherein LOU064 treatment is discontinued due to vaccination, particularly wherein LOU064 treatment is discontinued for 5-10 days (e.g., 7 or 8 days), preferably 6 weeks prior to vaccination and resumed after vaccination, e.g., 5-20 days, preferably 5-10 days, or more preferably 10-15 days after vaccination. In alternative embodiments, vaccination is performed with a live vaccine and / or an attenuated vaccine. In a particular aspect of this embodiment, after discontinuation of LOU064 treatment (e.g., 5-10 days or 7 or 8 days after discontinuation of LOU064 treatment), the patient receives a quadrivalent influenza vaccine, a PPV-23 vaccine, or a KLH neoantigen vaccine. In one aspect of this embodiment, patients receiving the quadrivalent influenza vaccine achieve a response defined as a >4-fold increase in antihemagglutinin antibody titers compared to baseline at 28 days post-vaccination. In another embodiment, patients receiving the PPV-23 vaccine achieved a >2-fold increase in IgG titers compared to baseline 28 days post-vaccination. In yet another embodiment, patients receiving the KLH neoantigen vaccine achieved a T-cell-dependent antibody response, as measured by anti-KLH IgG and IgM titers, 28 days post-vaccination. LOU064 treatment then continued on day 29 post-vaccination. LOU064 or a pharmaceutically acceptable salt thereof can be conveniently administered orally. The duration of oral therapy using the pharmaceutical composition disclosed herein will vary depending on the severity of the disease being treated and the condition and individual response of each patient. Healthcare providers will use the pharmaceutical composition disclosed herein to determine the appropriate duration of oral therapy and the timing of its administration. In some embodiments, HS patients are treated according to the claimed method for at least 16 weeks, at least 24 weeks, at least 36 weeks, at least 48 weeks, or at least 52 weeks. In some embodiments, HS is treated with prolonged use. In one embodiment, the pharmaceutical composition of the present invention for use in the prevention or treatment of HS may be a unit dose of about 25 mg to about 100 mg of one or more active ingredients for a subject weighing about 50-70 kg. The therapeutically effective dose of the compound or pharmaceutical composition depends on the subject's species, weight, age and individual circumstances, and the severity of the contrast agent-induced nephrotic disorder. A physician, clinician, or veterinarian with ordinary skills can readily determine the effective amount of each active ingredient necessary for the prevention, treatment, or inhibition of the disorder or disease progression. A preferred formulation is a capsule or tablet composition comprising about 25 mg to about 100 mg of LOU064, and one or more excipients independently selected from fillers, disintegrants, binders, and, if desired, lubricants and flow aids. In a preferred embodiment, the capsule or tablet composition comprises about 25 mg of LOU064 or a pharmaceutically acceptable salt thereof, and one or more excipients independently selected from fillers, disintegrants, binders, and, if desired, lubricants and flow aids. In another embodiment, the capsule or tablet composition comprises about 50 mg or about 100 mg of LOU064, and one or more excipients independently selected from fillers, disintegrants, binders, and, if desired, lubricants and flow aids. This article discloses methods for treating hidradenitis suppurativa (HS), which include administering, orally to a patient in need, a dose of about 50 mg to about 200 mg of LOU064 or a pharmaceutically acceptable salt thereof daily. The dose may be administered to the patient on a once-daily or twice-daily basis. In another embodiment, the method includes administering, orally to a patient in need, a dose of about 25 mg to about 100 mg of LOU064 twice daily (BID). In a preferred aspect of this embodiment, the method includes administering, orally to the patient, a dose of about 25 mg of LOU064 twice daily (BID). In another preferred aspect of this embodiment, the method includes administering, orally to the patient, a dose of about 100 mg of LOU064 twice daily (BID). In a preferred embodiment of the disclosed methods, uses, and kits, the patient achieves a sustained response one year after treatment, as measured by the (Simplified) Hidradenitis Suppurative Clinical Response (HiSCR), HiSCR50, HiSCR75, HiSCR90, Numerical Rating Scale (NRS), Hidradenitis Suppurative Physician Overall Assessment (HS-PGA), or Dermatology Quality of Life Index (DLQI), Severity of HS Assessment (SASH), or International Severity of HS Scoring System (IHS4). In a preferred embodiment of the disclosed methods, uses, and kits, the patient had previously been treated with a systemic medication prior to treatment with LOU064 as disclosed herein. In a preferred embodiment of the disclosed methods, uses, and kits, the systemic medication is selected from the group consisting of: local therapies, antibiotics, immunosuppressants, TNF-α inhibitors, IL-1 antagonists, and combinations thereof. In some embodiments of the disclosed methods, uses, and kits, the patient had not previously been treated with systemic agents or local treatments for HS prior to treatment with LOU064 as disclosed herein (i.e., the patient was treatment-naïve or bio-naïve). In one embodiment of the disclosed methods, uses, and kits, LOU064 (or a pharmaceutically acceptable salt thereof) as described herein is administered in combination with at least one of an antibiotic, a JAK inhibitor, a TYK2 inhibitor, a PDE4 inhibitor, or an immunosuppressant. In preferred embodiments of the disclosed methods, uses, and kits, the dosage of LOU064 as described herein is about 25 mg to about 100 mg BID. In other preferred embodiments of the disclosed methods, uses, and kits, the dosage of LOU064 is about 25 mg BID or 100 mg BID. In a preferred embodiment of the disclosed methods, uses, and kits, the patient suffers from moderate to severe HS. As used in this article, the phrase "moderate to severe" refers to HS disease in which the patient has ≥ 3 active inflammatory lesions [i.e., deep inflammatory lesions, such as abscesses and / or inflammatory nodules], no more than 15 fistulas, and the HS lesions involve at least two anatomical regions. In a preferred embodiment of the disclosed methods, uses, and kits, the patient is an adult. In some embodiments of the disclosed methods, uses, and kits, the HS patient is an adult with moderate to severe HS disease. In some embodiments of the disclosed methods, uses, and kits, the patient is an adolescent patient (age > 12 years). In some embodiments, the patient is an adolescent patient with moderate to severe HS. In some embodiments of the disclosed methods, uses, and kits, the patient has been diagnosed with HS for at least one year. In some embodiments of the disclosed methods, uses and kits, the patient does not have extensive scarring due to HS (i.e., <20 fistulas, with or without drainage, preferably no more than 15 fistulas). In some embodiments of the disclosed methods, uses, and kits, the patient had previously responded poorly to conventional systemic HS therapy. In a preferred embodiment of the disclosed methods, uses, and kits, the patient has an HS-PGA score of ≥ 3 prior to treatment with LOU064. In a preferred embodiment of the disclosed method, use, and kit, the patient achieves (simplified) HiSCR by week 16 of treatment. In a preferred embodiment of the disclosed method, use, and kit, the patient achieves NRS30 (e.g., pain NRS30 or skin itching NRS30) by week 16 of treatment. In a preferred embodiment of the disclosed method, use, and kit, the patient's HS redness and swelling decreased by week 16 of treatment. In a preferred embodiment of the disclosed method, use, and kit, the patient achieves a reduction of ≤ 6 by week 16 of treatment, as measured by DLQI. In a preferred embodiment, when the disclosed methods, uses, or kits are used to treat a patient population with moderate to severe HS, at least 40% of the patients achieve HiSCR (sHiSCR, HiSCR50, HiSCR75, or HiSCR90) in response to the administration step up to week 16 of treatment. In another preferred embodiment, when the disclosed methods, uses, or kits are used to treat a patient population with moderate to severe HS, the difference between the response rate at week 16 of treatment (e.g., patients who achieve a HiSCR response (sHiSCR, HiSCR50, HiSCR75, or HiSCR90 response) to placebo-treated patients is at least 15%, at least 25%, or at least 30%. In a preferred embodiment of the disclosed methods, uses, and kits, patients experienced a reduction in their modified Sartorius score after 16 weeks of treatment. In a preferred embodiment of the disclosed methods, uses, and kits, patients showed improvement in DLQI after 16 weeks of treatment. In a preferred embodiment, when the disclosed methods, uses, or kits are used to treat a patient population with moderate to severe HS, at least 25% (and preferably at least 30%) of the patients achieve an NRS30 response by week 16 of the administration step. In a preferred embodiment, when the disclosed methods, uses, or kits are used to treat a patient population with moderate to severe HS, less than 15% of the patients experience HS redness and swelling during the 16-week treatment period in response to the administration steps. In a preferred embodiment of the disclosed methods, uses, and kits, the patient is additionally treated with at least one topical medication and at least one antibacterial agent in combination with LOU064 as described herein. In a preferred embodiment of the disclosed methods, uses, and kits, the patient is treated with LOU064 as described herein for at least 16 weeks, at least 24 weeks, at least 36 weeks, at least 48 weeks, or at least 52 weeks. Most preferably, the patient receives treatment for at least 16 weeks. In a preferred embodiment of the disclosed method, use and kit, the patient’s pain is relieved as early as one or two weeks after the first dose of LOU064 (as measured by VAS or NRS, preferably NRS). In a preferred embodiment of the disclosed method, use, and kit, the patient’s pruritus is reduced (as measured by NRS) as early as one or two weeks after the first dose of LOU064. For example, the patient achieves NRS 30 for pruritus one or two weeks after the first dose of LOU064. In a preferred embodiment of the disclosed method, use and kit, the patient’s CRP decreased (by about 25% to about 30%) as early as one or two weeks after the first dose of LOU064 (as measured using a standard CRP assay). In a preferred embodiment disclosed herein, LOU064 is the anhydrous crystalline form A of the free base as disclosed in WO 2020 / 234779 (Example 1). In one aspect of this embodiment, LOU064 crystalline form A is in a substantially pure phase. Overview Details of one or more embodiments of this disclosure are set forth in the appended specification. Preferred methods and materials are now described, but any methods and materials similar or equivalent to those described herein may also be used in the practice or testing of this disclosure. Other features, objectives, and advantages of this disclosure will be apparent from the specification and the claims. In this specification and the appended claims, the singular form includes plural references unless the context clearly indicates otherwise. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains. All patents and publications cited in this specification are incorporated herein by reference. The following examples are provided to more fully illustrate preferred embodiments of this disclosure. These examples should in no way be construed as limiting the scope of the subject matter of the disclosure as defined by the appended claims. Example Abbreviations AE (Adverse Effects) bid or BID (Twice daily, once daily) ECG (Electrocardiogram) PK (Pharmacokinetics) PD (Pharmacodynamics) po (Oral) (by mouth = oral) Example 1 LOU064 signature in the transcriptomic dataset of hidradenitis suppurativa (genes downregulated by LOU064) Figure 1: Gene expression was measured in skin from healthy donors and in lesion and non-lesion skin from HS patients using the Affymetrix HG-U133 Plus 2 gene chip (GSE148027). We found that BTK expression (as measured by probe 205504_at) was significantly upregulated in lesion (but not non-lesion) skin compared to healthy controls. Figure 2 shows the LOU signature (LOU064-repressed genes) in a (large) transcriptomic dataset of hidradenitis suppurativa. The LOU064 signature was generated by stimulating whole blood with IgM followed by treatment with LOU064. The transcriptomic profiles of these samples were measured using Ampliseq. The 52 genes that we found to be significantly downregulated by LOU064 (FDR < 0.05 compared to stimulation alone) were defined as "LOU signatures". A large amount of transcriptomic data was measured using Affy microarrays (Carlos A. Penno et al., J. Invest. Dermatol. [Journal of Dermatological Research] 2020, Vol. 140, No. 21, 2421-2432.e10) - 49 of the 52 characteristic marker genes were also present in the data and were targeted by a total of 106 probes (each gene may be targeted by multiple probes). These 106 probes were used for feature enrichment using an algorithm called GSVA (Sonja Hanzelmann et al., BMC Bioinformatics [BMC Bioinformatics] 2013, 14(7) - https: / / doi.org / 10.1186 / 1471-2105-14-7), which calculates the enrichment of these 106 probes compared to all other measurement probes for each sample (General approach to genomic enrichment: Aravind Subramanian et al., PNAS [Proceedings of the National Academy of Sciences] 2005, 102(43) 15545-15550). The results are shown in Figure 1. The Wilcoxon test was used to show significantly different feature enrichment between healthy and diseased HS samples (p ~ 2.7e-7). This data demonstrates the upregulation of the LOU064 repressor gene (LOU064 signature) in hidradenitis lesions. Example 2 The basic principle of dosage Assuming no interspecies differences are associated with conversion and drug efficacy, the conversion PK / PD model simulations described below were used to predict human peripheral tissue occupancy (e.g., spleen and lymph nodes) of ramibrutinib. The PK / PD model focused on B cells, which, as mentioned above, are reportedly the primary targets of BTK inhibition in B-cell lineage HS. Besides the circulating portion, B cells typically reside in lymph nodes and the spleen. In HS, B cells are also present in so-called "tertiary lymphoid organs" within the HS lesion tissue, resembling key lymph nodes and germinal centers. Compared to circulating B cells in peripheral blood, B cells residing in the spleen, lymph nodes, or tertiary lymphoid organs in HS lesions are believed to exhibit faster BTK conversion. The conversion PK / PD model simulations guided dose selection for treating HS with LOU064. use LOU064 translation PK / PD Model prediction BTK occupancy rate Due to the pharmacological properties of LOU064 (irreversible binding), BTK occupancy in the blood is not a reliable biomarker for dose selection. Full occupancy can be achieved even at low doses before pharmacological activity is demonstrated by other biomarkers (CD63, CD203c, skin prick test). Tissue occupancy may be a better indicator of the expected efficacy of LOU064. Target The aim of this analysis was to characterize the pharmacokinetics (PK) of LOU064 in healthy volunteers and to simulate BTK occupancy in human spleen / tissue across a range of doses and dosing regimens (BID vs. QD) using a previously developed translational target occupancy model. Data Pharmacokinetic data from a Phase I clinical trial reported by Kaul et al. (2021) were used in the current analysis, including 102 patients. Methods A two-step approach was used to develop a translational target occupancy model to simulate BTK occupancy in the spleen / tissue. In the first step, a population PK model was established to characterize the LOU064 PK data from the Phase I clinical study reported by Kaul et al. (2021). In the second step, parameter estimates from the population PK model were used to develop a BTK occupancy model to predict BTK occupancy in blood and spleen / tissue. Finally, the BTK occupancy model was used to predict BTK occupancy in spleen / tissue at different dosage regimens (QD, BID). Results Population PK models have been developed to describe interim PK from a Phase I clinical study reported by Kaul et al. (2021). To address the variability in clearance after repeated dosing at doses below 50 mg (lower steady-state clearance on day 12 compared to day 1, with no difference at higher doses), clearance was modeled as a function of exponential time decay for both doses below 50 mg and doses above 50 mg. Overall, the resulting population model describes the PK data fairly well. PK parameter estimation was used to shift the BTK occupancy model to simulate BTK occupancy at steady state. BTK occupancy simulations showed that BID dosing was more effective than QD dosing at the same dose level, achieving a higher BTK occupancy (trough or average over a 24-hour interval). For the selected dose amounts of QD and BID regimens, the steady-state BTK occupancy at trough and mean values ​​over 24 hours for dosing regimens of 10 mg, 35 mg, and 100 mg once daily and 10 mg, 25 mg, and 100 mg twice daily is shown in Figure 4A (trough BTK occupancy during steady-state 24 hours) and Figure 4B (mean BTK occupancy during steady-state 24 hours), respectively. Both figures show that daily doses up to 200 mg (100 mg BID) may be required to achieve a BTK trough occupancy ≥ 80% in peripheral target tissues. Simulations were performed to compare different dosing regimens. Figure 3 shows a comparison of spleen BTK occupancy over time in steady-state simulations of 100 mg BID versus 100 mg QD. The figure shows that BID dosing resulted in higher occupancy with less variation compared to QD dosing, as expected from the basic principles. Conclusion: The model predicts that a significantly higher overall BTK occupancy rate can be achieved using a bid-only dosing regimen. While the predicted BTK trough occupancy rate in human tissues is approximately 70%–95% with a 25 mg bid-only dosing regimen, the model predicts that a 100 mg bid-only dosing regimen will achieve a ≥90% BTK trough occupancy rate. Example 3 Clinical trial design Double-blinding of subjects and investigators allows for unbiased assessment of subjective readings, such as the lesion count of HS or the overall HS-PGA score, as well as adverse events. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study was conducted to evaluate the efficacy, safety, and tolerability of several active therapeutic compounds, such as LOU064 (ramibrutinib), in subjects with moderate to severe hidradenitis suppurativa (HS). Following a screening period, the treatment period was 16 weeks, followed by approximately 4 weeks of safety follow-up. Subjects were given LOU064 at 25 mg twice daily (BID po), 100 mg twice daily (BID po), or placebo twice daily (BID po). Approximately 70 subjects were randomized, with 60 receiving the active compound (30 receiving 100 mg twice daily (BID), 30 receiving 25 mg twice daily (BID po), and 10 receiving placebo. The primary objective was to demonstrate the preliminary efficacy of LOU064 treatment compared to placebo in HS subjects after 16 weeks of treatment. A 4-week follow-up period was conducted after the 16-week treatment period to observe whether the sustainability of this effect after 16 weeks of treatment could be maintained or improved. Summary of Plans One or more primary objectives: The primary objective of this study was to evaluate the efficacy of ramibrutinib in patients with moderate to severe inflammatory HS compared with placebo by comparing the proportion of patients who achieved a clinical response as defined by the simplified hidradenitis suppurativa clinical response (HiSCR) after 16 weeks of treatment. Secondary objective: To assess the safety and tolerability of remibrutinib in patients with moderate to severe hidradenitis suppurativa (HS) by the following: (i) the number and severity of adverse events (AEs), and (ii) physical examination, vital signs, safety laboratory measurements, and ECG at baseline, and repeated until the study completion visit. Study Design: This is a non-validating, randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy, safety, and tolerability of ramibrutinib in subjects with moderate to severe hidradenitis suppurativa. For ramibrutinib, the maximum duration of participation in any single cohort shall not exceed 25 weeks, and will include a 35-day screening period, a 16-week treatment period, and will end with a 4-week safety visit. Treatment includes LOU064 (ramibrutinib), 100 mg bidpo or 25 mg bidpo, or placebo, from day 1 (week 1) to day 113 (week 17). Subjects will be randomized to the ramibrutinib treatment group or their corresponding placebo group in a 3:3:1 ratio. Population: Adult male and female participants aged 18 to 65 years who presented with moderate to severe hidradenitis suppurativa and were diagnosed with recurrent inflammatory lesions at least 12 months prior to screening. Key inclusion criteria: Male and female subjects aged 18 to 65 years (inclusive) with a clinical diagnosis of HS at least 12 months prior to screening; minimum weight at screening of 50 kg (inclusive); patients with moderate to severe HS as assessed at screening (before day 1 dosing): - at least 3 inflammatory lesions in total, i.e., abscesses and / or inflammatory nodules, and - no more than 15 fistulas, and - HS lesions must involve at least two anatomical regions. Key exclusion criteria: - Use of other investigational drugs at screening or within 30 days or 5 half-lives (whichever is longer) of randomization; or if local regulations require a longer period of use of other investigational drugs; - Women who are physiologically capable of pregnancy unless they used effective contraception during dosing and for at least 2 weeks after the last administration of remibrutinib; - Significant bleeding risk or coagulation disorders such as: o History of gastrointestinal bleeding, such as that associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) and that is clinically relevant: o Use of anticoagulants [e.g., warfarin or novel oral anticoagulants (NOACs)] within 2 weeks prior to randomization; o International normalized ratio (INR) greater than 1.5 at screening; o Use of antiplatelet drugs [including dual antiplatelet therapy (e.g., acetylsalicylic acid + clopidogrel)] within 2 weeks prior to randomization. Note: Monotherapy with acetylsalicylic acid (up to 100 mg / day) or clopidogrel is not excluded. Major surgery performed within 8 weeks prior to screening or planned surgery during study treatment. Key efficacy assessments: - Simplified and original Hidradenitis Suppurative Clinical Response (HiSCR) rate - Internationalized Hidradenitis Suppurative Severity Scoring System (IHS4) - Hidradenitis Suppurative - Physician Overall Assessment (HS-PGA) score and responder rate - HS inflammatory lesion count - Severity Assessment of Hidradenitis Suppurative (SAHS) Key safety assessments: - Number and severity of adverse events (CTCAE v5.0 classification) - Physical examination, including vital signs, safety laboratory measurements, and ECG. Other assessments: - PK - Pruritus NRS (Group D) - Patient-reported results include Numerical Rating Scale for Skin Pain (NRS), Dermatology Quality of Life Index (DLQI), and Patient Overall Assessment (PGA). Target Additional reference for clinical assessment: • The simplified HiSCR was chosen as the primary endpoint. The original HiSCR used in the phase 3 clinical trial with adalimumab (Kimball et al. 2016) The HiSCR (New England Journal of Medicine) has been validated (N Engl J Med 375:422-34). A simplified HiSCR is defined as a 50% reduction in the total number of abscesses plus inflammatory nodules, without an increase in draining fistulas. However, contrary to the original HiSCR, an increase in abscesses is permitted to constitute a clinical response if the previous criteria are met. • Inflammatory lesions of HS within typical anatomical areas will be counted as individual lesions (inflammatory nodules, abscesses, and draining fistulas). In addition to the count, a holistic assessment scale (Hyperpigmentation Suppurative Physician Holistic Assessment or HS-PGA) and a comprehensive score (Hyperpigmentation Severity Assessment Score or SAHS) will be used. Abscesses and nodules will also be presented as AN counts. • HS-PGA (Hyperpigmentation Suppurative-Physician Holistic Assessment): This score will be used as an exploratory target for assessing HS and is used in and described in Kimball AB, Kerdel F, Adams D, et al. (2012). [Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial.] Ann Intern Med;157:846-55. • The SAHS score is a comprehensive score (Hessam S, Scholl L, Sand M et al. (2018) A Novel Severity Assessment Scoring System for Hidradenitis Suppurativa). JAMA Dermatol [Journal of the American Medical Association Dermatology] ;154(3):330-335.), and will extract the collected information for inflammatory lesion counts, fistula counts and NRS pain. In addition, anatomical areas and new or swollen existing boils will be collected in both groups. • Several patient-reported outcomes will be used, including the Dermatology Quality of Life Index (DLQI). Finally, since skin-related pain is the most important symptom from the participants' perspective, a numerical rating scale for pain (NRS) will be included. • Other patient-reported outcomes (PROs) will include the Dermatology Quality of Life Index (DLQI) as a dermatology-related quality of life (QoL) tool (with a validated score available in many countries and multiple languages). It will also include a holistic patient assessment. • Skin pain - NRS (Numerical Rating Scale for Pain): Using the NRS for skin-related pain in adalimumab studies (Kimball et al. (2016)). N Engl J Med [New England Journal of Medicine] 375:422-34), and uses it as a symptom of skin or HS-related pain, which is one of the greatest burdens on patients (Matusiak et al. (2017)). J Am Acad Dermatol;76:670-5). The mean and worst values ​​(within the most recent 24 hours) of HS-related pain will be recorded. • Since itching is now considered a symptom in patients with HS, pruritus NRS is also included (Nguyen et al. 2021, Fernandez et al. 2021). Example 5 : 100 mg Film-coated tablets The following describes a preferred pharmaceutical composition (film-coated tablet). Example 6 : 50 mg Film-coated tablets The following describes a preferred pharmaceutical composition (film-coated tablet). Example 7 : 25 mg Film-coated tablets The following describes a preferred pharmaceutical composition (film-coated tablet). Example 8 : LOU064 security The safety of LOU064 has been tested in Phase I and II pharmacokinetic and clinical pharmacology studies in healthy subjects, as well as in Phase II / III clinical trials in patients with indications other than MS (particularly chronic spontaneous urticaria (CSU) and Sjögren's syndrome (SjS)). Short-term safety of LOU064 was assessed in the Phase I clinical trial. LOU064 is available as a single dose or multiple doses over 18 days, with doses ranging from 0.5 mg to 600 mg over 18 days. Furthermore, its short-term safety was demonstrated in a Phase I clinical study with 100 and 200 mg bids over 12 days (Kaul, M. et al. (2021). Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial. Clinical and Translational Science. 10.1111 / cts.13005). Summary of safety in the Phase 2b (extension) study in CSU subjects (interim results). In a 52-week open-label extension study, the long-term safety and tolerability of LOU064 were evaluated in eligible subjects with CSU who participated in a phase 2b study, using a dose of 100 mg bid. Based on an interim analysis of 100 subjects who received at least one dose of LOU064 and had a median exposure of 17.86 weeks (range: 2.9 weeks to 44.7 weeks), no safety signals were observed. At the cutoff, 93 subjects (93%) were still in the study, and 7 subjects had discontinued the study; no discontinuation was due to adverse events. Table 4 presents a summary of safety data observed in the Phase 2b study up to the interim analysis cutoff date. [Table 4] Interim analysis of open-label extended studies: death, other serious or clinically significant adverse events or related discontinuation (safety set) Fifty-eight subjects (58%) experienced at least one adverse event (AE) during treatment. Most AEs were minor, did not lead to treatment discontinuation, and were of mild severity. The most frequently affected SOCs were infections and invasive diseases (14%), followed by skin and subcutaneous tissue disorders (13%), with no trend regarding specific adverse events. The most common adverse events with the best terminology (≥ 2%) were headache (6%), diarrhea (4%), dizziness (3%), and gastroenteritis (3%); no bleeding events (defined as events under extensive bleeding SMQ, PT including platelet aggregation abnormalities, decreased platelet aggregation, platelet aggregation inhibition, platelet dysfunction, abnormal platelet function tests, and platelet toxicity) or events under SOC hematologic and lymphatic system disorders were reported. Three SAEs were reported: ovarian cysts, chest pain, and appendicitis; none were considered to be related to the study drug. Conclusions of the Phase 2b study and the corresponding open-label extension study In summary, no safety findings were observed at any of the evaluated doses in the Phase 2b study. Furthermore, in the corresponding CSU extension study using an open-label LOU064 100 mg bid, no safety signals were observed in the 100 enrolled subjects as of August 31, 2020. The proposed maximum dose of 100 mg LOU064 bid is considered well-tolerated and has a favorable safety profile. Summary of Safety in the Phase 2b (Extension) Study in CSU Subjects (Interim Results / Patients with Median Exposure of 35.14 Weeks) In the above 52-week open-label extension study, the long-term safety and tolerability of LOU064 in eligible subjects with CSU who participated in the Phase 2b study at a dose of 100 mg bid were evaluated. A new interim analysis was performed on patients (N = 183) with a median exposure of 35.14 weeks, and the results were compared with the safety results in the randomized, double-blind, placebo-controlled Ph2b core study in adult patients with CSU who received up to 12 weeks (wk) of (1:1:1:1:1:1:1:1) remibrutinib 10 mg qd (once daily), 35 mg qd, 100 mg qd, 10 mg bid (twice daily), 25 mg bid, or 100 mg bid or placebo (NCT03926611). (Table 5) In long-term exposure to ramibrutinib (median 35.14 wks, N = 183), the proportion of patients experiencing at least one adverse effect (AE) during ramibrutinib treatment (57.4% [n = 105]) was similar to that in CS (presented with any dose of ramibrutinib) (58.1% [n = 155]; median 12.14 wks, N = 267). In ES, there were 4 serious adverse effects (SAEs), 6 AEs leading to treatment discontinuation, and no deaths. The incidence of AEs reported by major organ class (SOC) was similar in ES and CS: infection and invasiveness (23.0% and 24.0%), followed by skin / subcutaneous tissue disorders (17.5% and 16.9%) (Table 5). The incidence of AEs reported by preferred terminology was comparable in ES and CS, with headache (6.6% and 9.7%) being the most common. In ES, the incidence of AES such as infection (23%), bleeding (4.4%), and cytopenia (0.5%) was consistent with that in CS. Newly observed significant transaminase elevations were isolated in both ES (isolated ALT > 3xULN, normalized within 4 weeks, 1 patient discontinued treatment early for personal reasons) and CS (1 patient with ALT > 5xULN, treatment normalized). Analysis of laboratory parameters did not reveal significant safety issues, and no clinically significant changes in vital signs were observed. No significant ECG findings or QTs > 500 ms were noted in any patient. [Table 5]: Safety characteristics of remibrutinib (LOU064) in the Phase 2b core and extension studies (safety set). in conclusion Ramibrutinib demonstrated a favorable safety profile across the entire dose range, and no new safety signals were observed in patients with CSU who were exposed to a 100 mg bid dose for up to 52 weeks. Example 9 Evaluation goals and relevant endpoints of immune response modulation to three different types of vaccines by co-administration and discontinuation of remibrutinib in healthy subjects. Research Design Overall design This randomized, double-blind, placebo-controlled study has a parallel group design. Given an estimated dropout rate as high as 20%, approximately 90 healthy female and male participants of non-fertility potential will be randomly assigned to one of the three treatment groups to achieve a minimum of 72 evaluable completers. The study will include a 28-day screening period, a 43-day treatment period, and study completion evaluation within two weeks of the last administration of the study drug (day 57). A safety follow-up phone call will be made approximately 30 days after the last administration of the study drug (day 73). Participants will reside on days -1 to 1 and days 14–17. Overall, the maximum study duration for each participant is approximately 85 days. The effects of concomitant and discontinuation of ramibrutinib treatment on influenza / Pneumovax® 23 and Immucothel® were evaluated with reference to placebo. Research Implementation Screening and baseline Participants who meet the eligibility criteria at screening will be allowed to undergo baseline evaluation on day -1. All baseline safety evaluation results must be obtained prior to the first dose. At baseline, participants will be randomly assigned to one of the three treatment groups listed below. treat All participants received the study drug (ramibrutinib 100 mg or placebo twice daily) from day 1 to day 42 and returned to the clinic for a treatment completion visit on day 43. All participants also received a quadrivalent influenza vaccine, a PPV-23 vaccine, and a KLH neoantigen vaccine on day 15. Vaccinations were administered 3 hours after the study drug administration. During the clinical visit and during the stay (days -1 to 1 and 14-17), the study drug was administered to the participants by researchers at the clinic. After discharge from the clinical visit during the treatment period, the study drug, along with a medication diary, was provided to the participants for self-management at home. Safety assessment will include physical examination, ECG, vital signs, standard clinical laboratory evaluation (hematology, blood chemistry, urine analysis), and monitoring for adverse and serious adverse events. Multiple blood samples will be drawn from all participants on days 8, 15, and 36 to evaluate the pharmacokinetics of remibrutinib. Group A (Concomitant with remibrutinib treatment): Participants will receive a placebo (bid) from days 1 to 7, followed by treatment with ramibrutinib (100 mg bid) from days 8 to 15 of the study to achieve PK / PD steady state before the administration of the three vaccines on day 15. Participants will continue to receive ramibrutinib (100 mg bid) until day 42. Group B (Discontinuation of remibrutinib treatment): Participants will be treated with remibrutinib 100 mg bid from days 1 to 7 to achieve PK / PD steady-state conditions, followed by placebo (bid) from days 8 to 28, and three vaccines will be administered on day 15. Treatment with remibrutinib 100 mg bid will be restarted from days 29 to 42. Group C (Placebo): Participants in group C will receive a placebo (bid) from day 1 to day 42 and will receive three vaccines under the placebo condition on day 15. Key inclusion criteria • A signed informed consent form must be provided before participating in the study. • Healthy or mildly obese but otherwise healthy male participants aged 18 to 55 years (inclusive) and female participants without reproductive potential. • Participants should be in good health, as determined by their medical history, physical examination, vital signs, ECG, and laboratory tests shown at screening and baseline visits. • Vital signs (systolic and diastolic blood pressure and pulse rate) will be assessed in a sitting position and again (if required by the assessment schedule) in a standing position at screening and baseline. Sitting vital signs (after 3 minutes in a sitting position) must be within the following ranges: • Tympanic membrane temperature of 35.0°C to 37.5°C. • Systolic blood pressure (SBP) of 90 and 139 mmHg (inclusive). • Diastolic blood pressure (DBP) of 50 and 89 mmHg (inclusive). • Pulse rate of 45 and 90 bpm (inclusive). • Participants must weigh at least 50 kg to participate in the study, and their body mass index (BMI) must be between 18 and 34.9 kg / m2. • Participants must be willing to remain at the clinical center as required by the protocol and comply with the requirements / instructions outlined in the ICF. • Be able to read, speak and understand the local language in order to understand and comply with research requirements. Key Exclusion Criteria 1. Use other investigational drugs within 5 half-lives or 30 days (whichever is longer) before the first dose. 2. Current evidence of clinically significant ECG abnormalities or a history of clinically significant ECG abnormalities or a family history of QT prolonged syndrome or other cardiac conduction abnormalities (grandparents, parents, and siblings), a history of additional risk factors for torsades de pointes (TdP) (e.g., heart failure, hypokalemia), and / or a known history or current clinically significant arrhythmia. Abnormal ECG is defined as PR > 220 msec, QRS complex > 120 msec, QTcF > 450 msec in men and women, or any other morphological changes other than early repolarization, nonspecific ST or T wave changes. 3. A history of malignancy in any organ system, whether treated or untreated, within the past 5 years (excluding localized basal cell carcinoma of the skin or cervical cancer in situ, regardless of evidence of local recurrence or metastasis). 4. A history of or presence of any clinically significant disease in any major systemic organ class (including, but not limited to, cardiovascular, pulmonary, metabolic, hepatic, renal, hematologic, endocrine, neurological, or psychiatric disorders that have not been resolved within two weeks prior to initial administration). 5. Hypersensitivity to remibrutinib or drugs from the same compound class or their excipients. 6. Any contraindications to the use of Pneumovax 23, influenza, or KLH vaccines, including any acute infection, fever, or hypersensitivity reaction, or known hypersensitivity to any relevant component of the vaccine to be administered in this study (e.g., eggs or shellfish / KLH). 7. History of seasonal influenza vaccination in 2022–2023 or a known clinical diagnosis of influenza infection during the 2022–2023 influenza season prior to recruitment. 8. History of previous exposure to or immunization with KLH. none [Figure 1]: Enrichment of transcriptomic signatures (overexpression of genes in diseased HS samples) [Figure 2]: LOU signature (LOU064 repressor gene) in a (large) transcriptomic dataset of hidradenitis suppurativa. [Figure 3]: Simulation of BTK occupancy in the spleen at steady state. [Figure 4]: (A) Valley of BTK occupancy during a steady-state 24-hour period. The graph shows the median forecast as dots and the vertical line shows the 95% forecast range. (B) Average of BTK occupancy during a steady-state 24-hour period. The graph shows the median forecast as dots and the vertical line shows the 95% forecast range. [Figure 5]: The optimal particle size distribution of nano-LOU064. none

Claims

1. The use of a pharmaceutical composition for preparing a medicament for treating HS in patients requiring treatment of hidradenitis suppurativa (HS), wherein the pharmaceutical composition comprises remibrutinib.

2. The use as described in claim 1, wherein remibrutinib is administered daily at a dose of about 50 mg to about 200 mg, wherein the word "about" indicates an error of + / - 10%.

3. The use as described in claim 2, wherein remibrutinib is administered at a dose of about 25 mg twice daily to about 100 mg twice daily.

4. The use as described in claim 2, wherein remibrutinib is administered twice daily at a dose of approximately 100 mg.

5. The use as described in claim 2, wherein remibrutinib is administered twice daily at a dose of approximately 25 mg.

6. The use as claimed in any one of claims 1 to 5, wherein the administration period of remibrutinib is less than 3 months.

7. The use as claimed in any one of claims 1 to 5, wherein remibrutinib is administered over a period of up to 16 weeks.

8. The use as claimed in any one of claims 1 to 5, wherein the administration of remibrutinib has lasted for more than 6 months.

9. The use as claimed in any one of claims 1 to 5, wherein the pharmaceutical composition is administered as a single therapy.

10. The use as claimed in any one of claims 1 to 5, wherein the pharmaceutical composition is not administered in conjunction with a strong inhibitor of CYP3A.

11. The use as claimed in any one of claims 1 to 5, wherein the pharmaceutical composition is not administered in conjunction with a strong inhibitor of CYP3A4.

12. The use as claimed in any one of claims 1 to 5, wherein the pharmaceutical composition is administered in combination with one or more second therapeutic agents.

13. The use as claimed in any one of claims 1 to 5, wherein the patient has not previously been treated with systemic or local medications prior to treatment with remibrutinib.

14. The use as claimed in any one of claims 1 to 5, wherein the patient is selected according to at least one of the following criteria: a) the patient has moderate to severe HS; b) the patient has at least 3 inflammatory lesions prior to treatment with the remibrutinib; c) the patient has no extensive scarring (not more than 15 fistulas) due to HS prior to treatment with the remibrutinib; d) the patient has been clinically diagnosed with HS for at least 12 months; or e) the patient has at least two anatomical regions associated with HS lesions.

15. The use as claimed in any one of claims 1 to 5, wherein the patient achieves at least one of the following by week 16 of treatment: a) simplified HiSCR; b) reduction of HS erythema; c) pain reduction as measured by the pain NRS; d) reduction of skin pruritus as measured by the pruritus NRS; f) reduction of the total count of HS inflammatory lesions or the count of different types of HS inflammatory lesions; g) reduction of IHS4 score; h) a reduction of ≤ 6 as measured by DLQI; and / or i) improvement of DLQI.

16. The use as claimed in any one of claims 1 to 5, wherein when the pharmaceutical composition is used to treat a patient population with moderate to severe HS, at least 40% of said patients achieve at least one of the following by week 16: a) HiSCR50; b) HiSCR75; c) HiSCR90; or d) simplified HiSCR.

17. The use as claimed in any one of claims 1 to 5, wherein by week 16 of treatment, at least 25% of said patients achieve an NRS30 response; or less than 15% of said patients experience HS redness and swelling.

18. The use as claimed in any one of claims 1 to 5, wherein as early as one or two weeks after the first dose of remibrutinib, the patient has at least one of the following: a) pain reduction as measured by the pain NRS; b) skin pruritus reduction as measured by the pruritus NRS; or c) a reduction of at least 25% in CRP as measured by a standard CRP assay.

19. The use as claimed in any one of claims 1 to 5, wherein the patient achieves a sustained response 3 months after the end of treatment by means of values ​​measured by inflammatory lesion count, hidradenitis suppurativa clinical response (HiSCR), numerical rating scale for pruritus or pain (NRS), hidradenitis suppurativa-physician overall assessment (HS-PGA), HS severity assessment (SASH), International HS Severity Scoring System (IHS4) or Dermatology Quality of Life Index (DLQI).

20. The use as described in claim 19, wherein the patient achieves a sustained response 3 months after the end of treatment, measured by values ​​of a simplified HiSCR (sHiSCR), HiSCR50, HiSCR75, or HiSCR90.

21. The use as claimed in any one of claims 1 to 5, wherein remibrutinib is configured in the pharmaceutical composition, wherein the pharmaceutical composition comprises one or more pharmaceutically acceptable carriers, each of which is independently selected from fillers, lubricants, binders, disintegrants and glidants.

22. The use as described in claim 21, wherein the pharmaceutical composition is in tablet or capsule form.

23. The use as described in claim 21, wherein the pharmaceutical composition comprises nanoparticles of remibrutinib.

24. The use as claimed in claim 23, wherein the pharmaceutical composition comprises nanoparticles of remibrutinib having an average particle size between about 50 nm and about 750 nm as measured by PCS, wherein the word "about" indicates an error of + / - 10%.

25. The use as claimed in claim 21, wherein the pharmaceutical composition comprises remibrutinib and an adhesive in a weight ratio of about 2:1, wherein the word "about" indicates an error of + / - 10%.

26. The use as claimed in claim 25, wherein the pharmaceutical composition comprises remibrutinib, a binder, and a surfactant in a weight ratio of about 2:1:0.

08.

27. The use as described in claim 21, wherein the pharmaceutical composition comprises remibrutinib and an adhesive in a weight ratio of about 1:1, wherein the word "about" indicates an error of + / - 10%.

28. The use as described in claim 27, wherein the pharmaceutical composition comprises remibrutinib, a binder, and a surfactant in a weight ratio of about 1:1:0.

05.

29. The use as claimed in claim 21, wherein the pharmaceutical composition comprises remibrutinib, a polyvinylpyrrolidone-vinyl acetate copolymer as an adhesive, and sodium dodecyl sulfate as a surfactant.

30. The use as claimed in any one of claims 1 to 5, wherein remibrutinib is an anhydrous free base in crystalline form, characterized by an X-ray powder diffraction pattern containing one or more representative peaks, when measured at a temperature of about 25°C and an X-ray wavelength λ of 1.5405 Å, selected from the group consisting of the following peaks in terms of 2θ: 7.8 ± 0.2 °2θ, 9.2 ± 0.2 °2θ, 12.0 ± 0.2 °2θ, 13.6 ± 0.2 °2θ, 15.6 ± 0.2 °2θ, 16.0 ± 0.2 °2θ, 17.8 ± 0.2 °2θ, 18.3 ± 0.2 °2θ, 18.7 ± 0.2 °2θ, 19.2 ± 0.2 °2θ, 19.9 ± 0.2 °2θ, 22.1 ± 0.2 °2θ. °2θ, 23.4 ± 0.2 °2θ, 23.9 ± 0.2 °2θ, 24.8 ± 0.2 °2θ, 25.2 ± 0.2 °2θ, 25.5 ± 0.2 °2θ, 27.2 ± 0.2 °2θ and 29.6 ± 0.2 °2θ, where the word "approximately" indicates an error of + / - 10%.

31. The use of a combination product for preparing a medicament for treating hidradenitis suppurativa (HS) in patients requiring treatment, wherein the combination product comprises a therapeutically effective dose of ramibrutinib and one or more therapeutic agents, the one or more therapeutic agents being a topical HS medicament, a systemic HS medicament, an antibacterial agent, or a photodynamic therapy agent.

32. The use as described in claim 31, wherein the one or more therapeutic agents are topical medications or antibacterial agents.

Citation Information

Patent Citations

  • Crystalline forms of a BTK inhibitor

    WO2020234779A1